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It has become apparent that the extracellular matrix (ECM) is important to maintain 
skeletal muscle homeostasis. Mutations in ECM components such as collagen VI and 
laminin 2, which result in truncated protein expression, cause muscular dystrophies. 
Duchenne muscular dystrophy (DMD), the most frequently occurring of the muscular 
dystrophies, is caused by mutations in dystrophin. Dystrophin is a central member of 
the dystrophin-associated protein complex (DAPC), which connects the cytoskeleton 
of the myofibre to the extracellular matrix. Therefore, when there is a mutation in 
dystrophin, the connection from the cytoskeleton to the ECM is severed, resulting in 
muscle pathology. 
The MMP (matrix metalloproteinase) and ADAMTS (A Disintegrin and 
Metalloproteinase with Thrombospondin motifs) families of secreted 
metalloproteases are the main mediators of ECM remodelling. The ADAMTS 
proteoglycanases, known to process hyalectan proteoglycans of the ECM, have been 
reported to have roles during morphogenesis and embryonic development through 
their processing of versican. Recent studies have identified Adamts5 expression 
during fetal myogenesis in the mouse, while Adamts5 expression was also shown to 
be decreased in mdx dystrophic muscle undergoing necrosis. Further, expression of 
versican is upregulated in muscle biopsies from DMD patients and is localised in 
fibrotic regions of the endomysium. 
These observations suggest a role for ECM remodelling by ADAMTS5 in myoblast 
fusion, muscle regeneration and disease. As such, the aim of this thesis was to 
investigate the expression and function of ADAMTS5 in myoblast fusion and muscle 
regeneration using in vitro and in vivo models, respectively. 
The data presented in this thesis showed that Adamts5 was expressed by the C2C12 
myogenic cell line and that its silencing inhibited myoblast fusion due to an 
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accumulation of ECM around myoblasts, therefore likely preventing cell-cell contact 
required for myoblast fusion. In contrast, Adamts5 was not expressed by primary 
myoblasts, but instead expressed by muscle connective tissue (MCT) fibroblasts, in an 
in vitro primary culture system. 
Adamts5 expression was also investigated in the mdx mouse model of DMD. We 
showed that Adamts5 was decreased in the quadriceps of the mdx mouse at three 
weeks, when the tissue is undergoing myofibre necrosis, compared to age-matched 
C57Bl/10 wild-type controls. Adamts5 expression was also localised to blood vessels, 
regenerating myofibres and interstitial cells likely to be MCT fibroblasts. Proteolysis 
of versican by ADAMTS proteoglycanases yields a versican fragment termed 
versikine. Versikine was localised to blood vessels and interstitial cells in mdx 
dystrophic muscle. 
Lastly, expression and function of Adamts5 was investigated using an in vivo model 
of muscle regeneration. Again, Adamts5 was localised to blood vessels, regenerating 
myofibres and interstitial cells, likely to be MCT fibroblasts, in regenerating muscle. 
Aspects of muscle regeneration including the inflammatory response after muscle 
injury and regenerative myogenesis were investigated in Adamts5-/- mice, however 
there was no change in either of these parameters. 
Future studies may include using mice deficient for multiple Adamts proteoglycanases 
or a versican knockin mouse model, resistant to proteolysis by Adamts 
proteoglycanases, in order to further investigate ADAMTS proteolysis of versican in 








1.1.1 Structure and function
Skeletal muscle represents a large percentage of body mass and functions primarily to 
produce force that is necessary for movement, while also critical for metabolism, 
thermoregulation and breathing via the diaphragm muscle. 
Skeletal muscle has a highly organised structure which is composed of multinucleated 
cells (myofibres) spanning the length of the muscle (Figure 1.1). Within the myofibres 
are myofibrils which are composed of repeating sarcomere units. Sarcomeres are the 
functional units of muscle which are primarily composed of actin and myosin 
filaments responsible for muscle contraction. 
 
Figure 1.1 Structure of skeletal muscle.
This schematic shows the structural levels of skeletal muscle. The muscle is composed of 
multiple fascicles (groups of myofibres). The ultra-structure of the myofibre is also depicted 
including the myofibrils which are composed of repeating sarcomere units which are 
responsible for muscle contraction. Figure from (Relaix and Zammit, 2012). 
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1.1.2 Myogenesis: formation of skeletal muscle
Myogenesis, a complex and highly regulated process, is the formation of skeletal 
muscle from progenitor cells. Skeletal muscle is derived from embryonic progenitors 
of the dermomyotome, the dorsal portion of the somites. These progenitors 
delaminate from the dermomyotome and migrate to the limb bud (for the 
development of limb muscle) at approximately embryonic day 10.5 (E10.5). The 
progenitors proliferate in the limb bud and are specified to the myogenic lineage 
(Buckingham et al., 2003, Murphy and Kardon, 2011). 
Myogenesis occurs in four distinct phases throughout life (Biressi et al., 2007). 
Embryonic myogenesis of the mouse limb occurs between E10.5 and E12.5 and forms 
a series of primary fibres which establish the basic muscle pattern. In contrast, fetal 
myogenesis (E14.5-P0) together with neonatal myogenesis (P0-P21) are critical for 
muscle growth and maturation. After the basic muscle pattern is established, fetal 
myoblasts fuse to primary myofibres and also with each other to form secondary 
myofibres (Chang and Rudnicki, 2014). Neonatal myogenesis results in a large 
increase in muscle mass. Rapid proliferation of neonatal myoblasts leads to a rapid 
increase in myonuclear number and myofibre growth (White et al., 2010). The final 
stage is adult myogenesis after P21. Satellite cells, which are the adult myogenic 
progenitors, are largely responsible for postnatal growth and regeneration of damaged 
muscle (Chang and Rudnicki, 2014). Satellite cells become quiescent at approximately 
P21, however they can be activated in order to proliferate and differentiate to repair 
damaged muscle (Yin et al., 2013). 
While each of the four myogenic phases are unique and serve different roles, they all 
involve proliferation of myogenic progenitors and their subsequent differentiation 
and fusion into myocytes and multinucleated myofibres. The proliferation, 
differentiation and fusion of myogenic progenitors can be studied using various model 
systems. As well as in vivo chick and Drosophila models (Abmayr and Pavlath, 2012, 
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Kim et al., 2015), cell culture in vitro models are used to investigate mechanisms of 
myoblast fusion and myogenic differentiation. The C2C12 immortalised cell line is a 
commonly used model (Yablonka-Reuveni and Day, 2011) as it is easily amenable to 
genetic manipulation and pharmacological studies. Primary myoblasts isolated from 
mice also represent an invaluable tool (Danoviz and Yablonka-Reuveni, 2012) as they 
are more physiologically relevant than cell lines (Shefer and Yablonka-Reuveni, 2008) 
and may also be used as donor cells for myoblast transplantation experiments (Rando 




1.2 The Extracellular Matrix
The extracellular matrix (ECM) is a complex and dynamic structure which is perhaps 
best known for its classical function as a structural support for cells. More recent 
studies in the field have also shown that ECM components function to affect growth 
factor bioavailability and cell signalling pathways. The main ECM components in 
skeletal muscle are collagens, laminins, and proteoglycans and these will be reviewed 
in this section. 
In skeletal muscle, the dystrophin-associated protein complex (DAPC) acts as a link 
that anchors the extracellular matrix to the cytoskeleton of the myofibre (Figure 1.2). 
The DAPC is composed of multiple components including dystrophin, dystroglycan 
and sarcoglycan. This link is crucial in maintaining skeletal muscle health since 
mutations in DAPC components, which lead to absent or truncated proteins, result in 
pathology. The most frequently occurring of these pathologies is Duchenne muscular 
dystrophy, caused by mutations in dystrophin, which will be reviewed further.  
Figure 1.2 The dystrophin associated protein complex connects the extracellular matrix to
the cytoskeleton.
The dystrophin-associated protein complex binds the extracellular matrix (shown as laminin 
and collagen) and the cytoskeleton (shown as F-actin) via the N-terminal domain (NTD) and 




There are 28 members of the collagen family. They are trimers composed of three  
chains which form a triple helix structure (Ricard-Blum, 2011). Collagen IV is a 
network-forming collagen and is a major component of the basement membrane 
which provides stability by cross linking laminin and other components into a highly 
organised supramolecular structure (Poschl et al., 2004). Collagen VI forms 
supramolecular beaded microfibrils and interacts with a number of molecules 
including collagen IV and biglycan (Bonnemann, 2011). Mutations in any of the 
collagen VI chains (COL6A1, COL6A2 or COL6A3) cause Ullrich congenital muscular 
dystrophy and the comparatively mild Bethlem myopathy (Lampe and Bushby, 2005). 
1.2.2 Laminins
Laminins are a family of basement membrane proteins which are heterotrimers 
composed of ,  and  polypeptide chains (Aumailley et al., 2005). They are major 
components of the basement membrane and together with collagen IV are 
instrumental in basement membrane assembly (Hohenester and Yurchenco, 2013). 
Basement membrane assembly is initiated by binding of laminin LG domains to 
integrins and dystroglycans on the cell surface (Yurchenco, 2011). 
The predominant types of laminin in skeletal muscle are the 2 laminins, however 
laminins containing the 4 and 5 chains are also found during embryonic 
development and muscle regeneration (Grounds et al., 2005). Demonstrating its 
importance in skeletal muscle physiology, mutations in LAMA2 (laminin 2 chain) 
cause MDC1A congenital muscular dystrophy (Helbling-Leclerc et al., 1995). 
1.2.3 Hyaluronan
Hyaluronan is a linear glycosaminoglycan (GAG) consisting of N-acetylglucosamine 
and glucuronic acid disaccharide repeats. It is unique in that it is the only non-
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sulphated GAG which is also not post-translationally modified (Hascall and Esko, 
2009).  
Hyaluronan is synthesised by transmembrane hyaluronan synthases (HAS) at the 
plasma membrane which are encoded by the HAS1, HAS2 and HAS3 genes (Itano and 
Kimata, 2002). Hyaluronan is extruded into the extracellular matrix during its 
synthesis, allowing for synthesis of very large polymers typically in the order of 105 
to 107 Da (Weigel et al., 1997, Tammi et al., 2002).  
Hyaluronan may exist in soluble form as a polymer, or it may form large complex 
aggregates with its hyaladherin binding partners (Jiang et al., 2011). Hyaluronan binds 
to a number of proteins termed hyaladherins which include cell surface receptors and 
ECM components. Hyaluronan binds to hyalectan proteoglycans and also to CD44, 
the main HA cell surface receptor, tethering hyaluronan to the cell surface through 
this binding (Toole, 2001).  
1.2.4 Proteoglycans and Sulphated Glycosaminoglycans
Proteoglycans are a complex family of molecules which consist of a protein core and 
GAG side chains. The major categories of proteoglycan are: transmembrane, which 
include the syndecans; basement membrane proteoglycans such as agrin and perlecan; 
hyalectans which include aggrecan, versican, neurocan and brevican; and the small 
leucine-rich proteoglycans (SLRPs) of which biglycan and decorin are examples 
(Iozzo and Schaefer, 2015). Biglycan and versican will be reviewed in further detail 
as they are ADAMTS5 substrates expressed in skeletal muscle and are therefore of 
relevance to this thesis. 
1.2.4.1 Biglycan
Biglycan is a SLRP encoding a 42 kDa core protein which contains multiple leucine-
rich repeats thought to be important for protein binding with other molecules (Bianco 
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et al., 1990). Biglycan has two GAG attachment sites at its N-terminal end to which 
GAG chains may be attached (Roughley and White, 1989). Biglycan may carry either 
one or two GAG chains on its core protein, adding further complexity to its structure 
(Esko et al., 2009). 
Biglycan is expressed in skeletal muscle as both a proteoglycan and as a core protein 
without GAG chains (Rafii et al., 2006). Biglycan binds to -dystroglycan, a central 
member of the DAPC, seemingly via its GAG chains since recombinant non-glycated 
biglycan core protein does not bind -dystroglycan (Rafii et al., 2006, Bowe et al., 
2000). 
In contrast, biglycan binding to collagen VI is independent of its GAG chains (Wiberg 
et al., 2001). Biglycan also binds -sarcoglycan and -sarcoglycan, independent of its 
GAG chains (Rafii et al., 2006). Further studies have shown that there is decreased 
expression of DAPC components at the sarcolemma in biglycan null mice, which is 
restored by intramuscular injection of recombinant biglycan (Mercado et al., 2006). 
Further to its interactions with binding partners, biglycan also directly affects growth 
factor signalling (Neill et al., 2015). Biglycan and the related SLRP decorin both bind 
TGF- . Both proteoglycan and core protein forms of the SLRPs are able to bind TGF-
, and the removal of GAG chains increases binding. This growth factor binding 
sequesters TGF-  and therefore reduces its bioactivity (Hildebrand et al., 1994). 
Biglycan can also bind VEGF, however its binding appears to potentiate and not 
inhibit its signalling, as seen in the case of TGF-  (Berendsen et al., 2014). Soluble 
biglycan also binds the toll-like receptors TLR2 and TLR4, initiating pro-
inflammatory signalling cascades (Schaefer et al., 2005, Neill et al., 2015). 
1.2.4.2 Versican
Versican, first discovered in the conditioned medium of fibroblasts, is a large 
aggregating proteoglycan of the hyalectan family (Wight et al., 2011). The gene is 
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located on mouse chromosome 13 (Vcan) and human chromosome 5 (VCAN) (Naso 
et al., 1995, Iozzo et al., 1992). The versican core protein is encoded by a 12 kb 
transcript spanning 15 exons (Wight et al., 2011). 
Versican is a large proteoglycan, approximately 400 kDa, consisting of an N-terminal 
G1 globular domain, central GAG binding regions and a C-terminal G3 domain 
(Figure 1.3) (Zimmermann, 2000, Wight, 2002). The G1 domain consists of an 
immunoglobulin-like fold and proteoglycan tandem repeats which are responsible for 
binding to link protein and hyaluronan, which are defining features of the hyalectans. 
The G3 domain includes an epidermal growth factor (EGF)-like domain, a lectin-like 
domain and a complement regulatory protein-like domain. 
The central GAG binding region is encoded by exons 7 and 8. The GAG-  domain is 
encoded by exon 7 and GAG-  domain by exon 8. Alternative splicing of these two 
exons results in four splice variants (Wight, 2002). Versican V0 is formed when both 
exons 7 and 8 are present, and therefore includes both GAG-  and GAG-  domains. 
Versican V1 is formed when exon 7 is spliced out, producing only the GAG-  domain, 
while versican V2 is formed when exon 8 is spliced out, producing only the GAG-  
domain. Versican V3 results from both exons 7 and 8 being spliced out, producing a 





Figure 1.3 Domain structure of the hyalectans.
The hyalectans are composed of N-terminal globular domains, central GAG binding regions 
and a C-terminal G3 domain. The versican splice variants are shown. V0 versican includes 
both GAG-  and GAG-  domains, V1 versican has GAG-  only, V2 versican has GAG-  only 
and V3 versican contains neither GAG domains. Figure from (Iozzo and Schaefer, 2015). 
Versican interacts with multiple binding partners, increasing the complexity of its 
biology. As mentioned previously, versican binds to hyaluronan via its G1 globular 
domain. Through its G3 domain, versican also binds molecules such as fibulins, 




1.3 Extracellular matrix remodelling
Extracellular matrix remodelling is the proteolysis of ECM components (Overall and 
Blobel, 2007). As well as being necessary for the ever-changing and dynamic nature 
of the ECM, particularly during embryonic development and morphogenesis, 
remodelling of the ECM also regulates processes such as cell signalling through the 
generation of matrikines, bioactive peptide fragments of ECM proteins which act as 
ligands for cell surface receptors (Wells et al., 2015). 
The main extracellular proteases involved in ECM remodelling are MMPs (matrix 
metalloproteinases) and members of the ADAMTS family. MMPs are multidomain 
proteins. They typically consist of a propeptide, a catalytic domain and other domains, 
such as a hemopexin domain, which vary between family members (Nagase et al., 
2006). They are grouped into categories, depending on domain organisation and 
known substrates, such as collagenases, gelatinases, stromelysins, and membrane-type 
MMPs (Nagase et al., 2006). 
1.3.1 ADAMTS proteoglycanases
The ADAMTS (A Disintegrin and Metalloproteinase with Thrombospondin motifs) 
are a family of 19 secreted metalloproteases (Apte, 2009, Stanton et al., 2011). They 
are multidomain proteins comprising a zinc-dependent catalytic domain, a disintegrin 
domain, thrombospondin motif(s), a cysteine-rich region and a spacer domain (Apte, 
2009, Stanton et al., 2011) (Figure 1.4). They are also modified by N-glycosylation, a 
modification necessary for secretion of ADAMTS9 (Koo et al., 2007) but not 




Figure 1.4 Domain structure of the ADAMTS family.
The structure of the ADAMTS family members is shown. Their structure includes a signal 
peptide, propeptide, catalytic domain, disintegrin domain and thrombospondin motif(s). 
Figure from (Stanton et al., 2011). 
The ADAMTS proteoglycanases are a sub-group of the ADAMTS family, classified by 
their known substrates and phylogeny (Nandadasa et al., 2014). Known substrates of 
the ADAMTS proteoglycanases include members of the hyalectan (Tortorella et al., 
1999, Sandy et al., 2001) and SLRP (Melching et al., 2006, Gendron et al., 2007) 
proteoglycan families. The sub-group comprises six members: ADAMTS1, ADAMTS4, 
ADAMTS5, ADAMTS9, ADAMTS15 and ADAMTS20 (Nandadasa et al., 2014). 
ADAMTS5, the focus of this thesis, is a member of the ADAMTS family, discovered 
less than two decades ago (Abbaszade et al., 1999, Hurskainen et al., 1999). ADAMTS5 
gained wide-spread interest after a series of studies identified it as an aggrecanase 
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(aggrecan-degrading protease) (Abbaszade et al., 1999). Aggrecan degradation in 
cartilage is a hallmark of arthritis progression, resulting in loss of joint function. Two 
independent studies showed that Adamts5 deficient mice were protected from 
experimentally induced arthritis, identifying ADAMTS5 as the major aggrecanase in 
the mouse (Stanton et al., 2005, Glasson et al., 2005). As a result of these and other 
subsequent studies, ADAMTS5 has become a major drug target for osteoarthritis, 
resulting in the development of aggrecanase inhibitors to target and prevent aggrecan 
degradation which leads to osteoarthritis (Chockalingam et al., 2011, Fosang, 2015, 
Larkin et al., 2015). 
Studies using Adamts deficient mice have demonstrated cooperative roles for 
ADAMTS members that are necessary for processes including palate formation 
(Enomoto et al., 2010) and regression of interdigital webs during embryonic limb 
development (McCulloch et al., 2009b). When investigating ADAMTS5, the other 
Adamts proteoglycanases therefore also need to be considered. As such, all ADAMTS 
proteoglycanases will be discussed further in this section. 
1.3.1.1 Synthesis of ADAMTS proteoglycanases
ADAMTS proteoglycanases are typically synthesised as inactive zymogens which 
include a propeptide. The inactive zymogens are activated by removal of the 
propeptide by proprotein convertases such as furin and PACE4 (Longpre and Leduc, 
2004, Wang et al., 2004, Longpre et al., 2009). The propeptide domain is also thought 
to be necessary for proper protein folding (Stanton et al., 2011). 
ADAMTS1 and ADAMTS4 are activated by furin in the trans-Golgi network (Longpre 
and Leduc, 2004, Wang et al., 2004). ADAMTS5 and ADAMTS15 are also synthesised 
as inactive zymogens but are activated extracellularly by furin (Longpre et al., 2009, 
Dancevic et al., 2013). In contrast, removal of the ADAMTS9 propeptide by furin, 
which occurs at the cell surface, diminishes its catalytic activity (Koo et al., 2007). 
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1.3.1.2 ADAMTS ancillary domain functions
While much of the attention directed towards the ADAMTS metalloproteases has 
focussed on their catalytic activity, the C-terminal domains, often referred to as 
ancillary domains (Apte, 2009), have also been shown to have important roles 
independent of catalytic activity. 
A recent study showed that binding of ADAMTS5, via its ancillary domains, to GAG 
chains of versican is necessary for versican proteolysis (Foulcer et al., 2014), while the 
thrombospondin repeats bind to TIMP3, an endogenous inhibitor of ADAMTS 
metalloproteases (Stanton et al., 2011). Ancillary domains of ADAMTS9 have also 
been implicated in its localisation and catalytic activity towards aggrecan and versican 
(Somerville et al., 2003). 
ADAMTS proteoglycanases have also been shown to modulate growth factor 
bioavailability and cell signalling pathways. ADAMTS1 modulates VEGF 
bioavailability through binding of VEGF via its C-terminal domains (Luque et al., 
2003). The same study also showed that this interaction with VEGF inhibits VEGFR2 
phosphorylation and endothelial cell proliferation (Luque et al., 2003). ADAMTS9, 
expressed in endothelial cells, also has anti-angiogenic activity (Koo et al., 2010). In 
contrast to ADAMTS1, the anti-angiogenic effect of ADAMTS9 is not through 
binding with VEGF, but appears to be due to its catalytic activity. Overexpression of 
catalytically active ADAMTS9 in endothelial cell cultures resulted in less tube-like 
structures being formed compared to empty vector control, while overexpression of 
catalytically inactive ADAMTS9 had no effect (Koo et al., 2010). More recently, 
ADAMTS5 was also shown to be anti-angiogenic, although this appears to be 
mediated by one of its thrombospondin motifs and independent of catalytic activity 
(Kumar et al., 2012). 
ADAMTS1 is also involved in regulating the bioavailability of TGF- . ADAMTS1 
activates TGF-  through its interaction with latency-associated peptide-TGF-  
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(Bourd-Boittin et al., 2011). These studies illustrate that although these ADAMTS 
proteoglycanases are highly homologous and share substrate specificity, the 
mechanisms through which they act are diverse. 
1.3.1.3 ADAMTS proteolysis of versican
Perturbed proteolysis of versican appears to be associated with multiple phenotypes 
in Adamts deficient mice (McCulloch et al., 2009b, Enomoto et al., 2010, Kern et al., 
2010). As such, ADAMTS proteolysis of versican will be reviewed further and is the 
focus of this thesis. 
Versican cleavage by ADAMTS proteoglycanases occurs at the Glu441-Ala442 position 
in the GAG-  domain of V1 versican (Glu1428-Ala1429 position for V0 versican, due to 
the inclusion of the GAG-  domain) (Sandy et al., 2001) producing a G1-DPEAAE 
fragment of versican, now termed versikine (Nandadasa et al., 2014). Versican 
proteolysis at this Glu441-Ala442 bond, generating the G1-DPEAAE (versikine) 
fragment, may be detected histologically or by Western blot, using a neo-epitope 
antibody developed to specifically recognise cleavage at that site (Sandy et al., 2001). 
ADAMTS1 and ADAMTS4 were the first of the ADAMTS proteoglycanases shown to 
process versican (Sandy et al., 2001), while later studies also showed that ADAMTS5 
(Longpre et al., 2009), ADAMTS9 (Somerville et al., 2003), ADAMTS15 (Dancevic et 
al., 2013) and ADAMTS20 (Silver et al., 2008) process versican at the same site. 
ADAMTS4 appears to be unique, in that it also cleaves the V2 versican splice variant 
(at position Glu405-Gln406) within the GAG-  domain (Westling et al., 2004). However, 
as expression of V2 versican is limited to the central nervous system (Dours-
Zimmermann et al., 2009), it is not directly relevant to this thesis. 
Biglycan is also processed by ADAMTS proteoglycanases (Melching et al., 2006, 
Gendron et al., 2007), however it is unclear whether lack of its processing in Adamts 
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deficient mice is of physiological relevance. Furthermore, a neo-epitope antibody to 




1.4 Duchenne muscular dystrophy
The muscular dystrophies are a diverse group of genetic disorders which result in 
progressive muscle wasting. Most are caused by mutations in genes encoding for 
components of the dystrophin-associated protein complex (DAPC) or the 
extracellular matrix which ordinarily provide mechanical stability (Mercuri and 
Muntoni, 2013). 
Duchenne muscular dystrophy (DMD) is the most frequently occurring of the 
muscular dystrophies. DMD is an X-linked genetic disorder that occurs in 
approximately 1:3,500 to 1:5,000 boys (Emery, 1991, Mendell et al., 2012) and is 
caused by mutations in the dystrophin (DMD) gene, the largest in the human genome 
consisting of 79 exons and spanning 2.2 Mb of DNA (Muntoni et al., 2003, Guiraud et 
al., 2015a). DMD is a lethal disease, characterised by progressive muscle wasting and 
weakness, for which there is no cure or effective treatment (Emery, 2002, Bushby et 
al., 2010). 
The DMD gene encodes for the 427 kDa dystrophin protein (Hoffman et al., 1987) 
which is a central component of the DAPC. Dystrophin is localised to the sarcolemma. 
It consists of four main domains: the N-terminal domain, central rod domain, a 
cysteine-rich domain, and a C-terminal domain (Koenig et al., 1988). The N-terminal 
domain binds F-actin while the cysteine-rich domain binds -dystroglycan, a central 
transmembrane DAPC component (Huang et al., 2000). The dystroglycan complex 
( -dystroglycan and -dystroglycan) interacts with the extracellular matrix, primarily 
via laminin 2, through its binding with -dystroglycan (Miner and Yurchenco, 
2004). Dystrophin therefore serves as a critical structural link between the 




1.4.1 DMD pathology and clinical progression
Most patients are diagnosed at five years of age, when delays in motor milestones 
become apparent (Bushby et al., 2010). Due to the progressive nature of the disease, 
muscle strength continues to deteriorate with age, and if left untreated, patients 
require the use of a wheelchair before their teens (Guiraud et al., 2015a). Life 
expectancy for DMD patients is approximately 19 years (Bushby et al., 2010). 
Therefore it is of great importance to recognise and diagnose suspected cases of DMD 
early in order to begin treatment as early as possible. 
Pharmacological intervention with glucocorticoids is the current standard of care for 
DMD which prolongs ambulation and slows the decline in muscle function (Bushby 
et al., 2004, Manzur et al., 2008). Life expectancy for patients has been extended into 
their fourth decade with the use of glucocorticoids, together with other interventions 
(Bushby et al., 2010). 
1.4.2 Mutations
The DMD gene has a relatively high mutation rate with one in three cases due to a de 
novo mutation (Laing, 1993). This means that most patients will have a unique 
mutation, further complicating diagnosis and development of new therapeutics 
(Aartsma-Rus et al., 2006). As of 2015 there have been 7,000 unique mutations 
identified in DMD patients (Bladen et al., 2015). 
Mutations in the DMD gene can cause either DMD or a comparatively milder form of 
muscular dystrophy, Becker muscular dystrophy (BMD). DMD is usually caused by 
frameshift mutations which alter the open reading frame, or nonsense mutations 
which introduce a premature stop codon. Frameshift mutations also usually result in 
the introduction of multiple premature stop codons. Consequently, translation is 
prematurely terminated and results in a non-functional truncated protein (Guiraud et 
al., 2015a). In contrast, BMD is usually due to mutations which maintain the open 
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reading frame, producing an internally truncated protein (Guiraud et al., 2015a). This 
means that the dystrophin protein is partially functional, comprising the critical N-
terminal and C-terminal domains that are responsible for linking the actin 
cytoskeleton to the extracellular matrix. Consequently, there is usually a later onset 
and slower disease progression in BMD patients (Emery, 2002). 
1.4.3 The mdx mouse model
Animal models are necessary for basic and pre-clinical research. The most commonly 
used DMD animal model is the mdx mouse. It has a naturally occurring point 
mutation in exon 23 of the Dmd gene resulting in a premature stop codon and loss of 
dystrophin (Bulfield et al., 1984). The mdx mouse has elevated plasma creatine kinase, 
a diagnostic feature it shares with DMD, however the pathology is less severe than 
that seen in DMD patients (Bulfield et al., 1984). Nonetheless, the use of the mdx 
mouse has proven crucial in furthering our understanding of DMD and has led to the 
development of clinical trials of novel therapies.
1.4.4 Potential therapeutics
There are currently a number of distinct approaches that researchers are taking to 
develop therapeutic strategies for DMD. Most approaches have limitations of some 
degree therefore necessitating this approach for multiple avenues of therapeutic 
development. 
1.4.4.1 Glucocorticoids
Although glucocorticoids are the current standard of care for DMD, their chronic use 
results in significant undesirable side effects (Matthews et al., 2016). VBP15 is a 
glucocorticoid analogue recently developed which improves muscle strength in the 
mdx mouse without the side effects (Heier et al., 2013). A Phase 1 clinical trial in 
healthy volunteers demonstrated tolerability (ClinicalTrials.gov Identifier: 
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NCT02415439) and a Phase 2a study with DMD patients has recently commenced 
(July 2016). 
1.4.4.2 CRISPR Cas9 genome editing
The CRISPR-Cas9 system is being investigated as a potential method of gene therapy 
in DMD. Three independent studies have used the strategy to restore dystrophin 
expression in the mdx mouse (Long et al., 2016b, Nelson et al., 2016, Tabebordbar et 
al., 2016), after an initial proof of concept study demonstrated the feasibility of editing 
the Dmd mutation in the germline of mdx mice (Long et al., 2014). 
While CRISPR-Cas9 mediated genome editing shows extraordinary promise, there 
are challenges which will need to be addressed. These include potential off-target 
effects, delivery methods, immunogenicity, and the longevity and efficiency of 
editing (Long et al., 2016a). 
1.4.4.3 Stop codon read through
Ataluren (Translarna; PTC124) is a small molecule identified in a high-throughput 
screen for its potential for translational read-through of premature stop codons (Peltz 
et al., 2013). As such, it would only be of benefit to DMD patients who have a 
nonsense mutation in the DMD gene. A Phase 3 trial was conducted and due to 
inconclusive results, the US Food and Drug Administration (FDA) has not approved 
ataluren, however its use in Europe has been conditionally approved (Sheridan, 2016). 
1.4.4.4 Exon skipping
The discovery that BMD patients produce partially functional, internally truncated 
dystrophin due to mutations which maintain the open reading frame, has led to the 
development of exon skipping treatments (Aartsma-Rus et al., 2009). Exon skipping 
involves “skipping” over exons during pre-mRNA splicing via delivery of antisense 
oligonucleotides (AON) which bind to the exon to be removed. Binding specificity is 
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due to the sequence of the AON, purposefully designed to be complementary to the 
sequence of interest. 
Limitations to this approach include that it is mutation-specific, which represents a 
challenge given that most patients have unique mutations due to the high mutation 
rate in the DMD gene (Aartsma-Rus et al., 2006). However, approximately 45-50% of 
patients have deletions of one or more exons between exon 45 and exon 55, therefore 
an approach designed to skip multiple exons in this region would be applicable to a 
large group of patients. Importantly, developing multiple AON compounds with 
distinct sequences would be both time consuming and economically unfeasible as 
each AON theoretically represents a distinct compound which requires its own 
separate clinical trials and regulatory approvals. 
Exon skipping trials to date include exon 51 skipping, applicable to approximately 
13% of DMD patients (Aartsma-Rus et al., 2009), using two different chemistries. 
Drisapersen (BioMarin Pharmaceutical) is a 2 OMePS (2 O-methylphosphorothioate-
modified) AON. Phase 3 trials were completed but its development by BioMarin 
Pharmaceutical was stopped after FDA approval was not granted because “the 
standard of substantial evidence of effectiveness has not been met” (Press release: 
www.biomarin.com). Exondys 51 (Eteplirsen; AVI-4658) is a PMO 
(phosphorodiamidate morpholino oligomer) AON developed by Sarepta Therapeutics 
also designed for exon 51 skipping. Data from a Phase 2 trial with 12 DMD patients 
showed promise (Mendell et al., 2016). While controversial, the FDA granted 
accelerated approval for Exondys 51 in September 2016, with the caveat that Sarepta 
Therapeutics was required to run a Phase 3 clinical trial to confirm evidence of 
Exondys 51 efficacy. 
Sarepta Therapeutics has also started to recruit for a phase 3 trial for exon 45 skipping 
and exon 53 skipping compounds (ClinicalTrials.gov Identifier: NCT02500381). The 
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trial aims to evaluate the efficacy of SRP-4045 (exon 45 skipping) and SRP-4053 (exon 
53 skipping), both of which use the same PMO backbone chemistry as Exondys 51. 
Exon 45 skipping and exon 53 skipping are applicable to approximately 8.1% and 7.7% 
of DMD patients respectively (Aartsma-Rus et al., 2009). 
1.4.4.5 Utrophin modulation
Utrophin is the autosomal homologue of dystrophin that is expressed during 
embryonic development. It is expressed at the sarcolemma and is homologous, in 
terms of its structure and function, to dystrophin. Since its expression is progressively 
replaced with dystrophin as adult myogenesis is reached, it was therefore reasoned 
that utrophin may be able to compensate for the absence of dystrophin, particularly 
since utrophin expression is also increased in DMD patients and mdx mice (Helliwell 
et al., 1992, Schofield et al., 1995). 
Utrophin modulation is a therapeutic strategy of relevance to all DMD patients, 
irrespective of their disease-causing mutation, making this an attractive approach. 
Small molecules such as SMT C1100 are being developed for utrophin modulation by 
Summit Therapeutics. SMT C1100 (ezutromid) is currently in a Phase 2 open-label 
clinical trial which started in June 2016 to assess its activity and safety in ambulatory 
DMD patients (ClinicalTrials.gov Identifier: NCT02858362). 
Biglycan, the small leucine-rich proteoglycan which binds DAPC components, is also 
being pursued as a potential DMD therapeutic. Pre-clinical work in the mdx mouse 
has shown that systemic delivery of recombinant biglycan (rhBGN) resulted in 
increased utrophin expression at the sarcolemma (Amenta et al., 2011). This was 
accompanied by increased sarcolemmal expression of other DAPC components 
including -sarcoglycan, 2-syntrophin and nNOS. rhBGN administration reduced 
dystrophic pathology in the diaphragm of the mdx mouse and improved muscle 
function, both shown to be utrophin-dependent as rhBGN did not improve pathology 
in the more severely affected mdx:utrn-/- dko mouse (Amenta et al., 2011). The 
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improvements may also be in part due to the ability of the biglycan core protein to 
sequester TGF-  (Hildebrand et al., 1994) therefore potentially acting as an anti-
fibrotic. rhBGN (TVN-102) is currently being developed by Tivorsan Pharmaceuticals 






Skeletal muscle injury can occur in several ways including contusion, laceration, 
crush or strain. Collectively, injury to skeletal muscle represents a significant public 
health problem, further compounded when muscular dystrophies are also taken into 
account (Gehrig and Lynch, 2011). Furthermore, incomplete muscle regeneration 
leads to development of fibrosis and consequently partial loss of functional muscle 
tissue (Mann et al., 2011). Development of fibrosis becomes catastrophic in muscular 
dystrophy since the chronic nature of muscle degeneration results in a large 
proportion of muscle mass becoming fibrotic, non-functional tissue. Therefore it is of 
great importance to understand the molecular mechanisms underlying muscle 
regeneration, with the aim of improving the process. Additionally, findings from 
muscle regeneration studies are also likely to be applicable to the muscular 
dystrophies, identifying potential therapeutic candidates. 
Commonly used experimental models of muscle regeneration include use of local 
anaesthetic (bupivacaine), freeze injury, chemicals (barium chloride; BaCl2) and 
myotoxins isolated from snake venom (cardiotoxin and notexin) (Gehrig and Lynch, 
2011, Hardy et al., 2016). These methods are commonly used because they are 
reproducible and follow a well characterised series of events. 
Damage to skeletal muscle initiates the regenerative response, which commences with 
myofibre necrosis and an inflammatory response. The initial inflammatory response 
includes the migration of neutrophils, macrophages and leukocytes to the injured 
tissue. There, they initiate the phagocytosis of necrotic tissue and cellular debris 
(Tidball and Villalta, 2010). 
During this initial period after injury, growth factors and cytokines, released by the 
damaged tissue and invading inflammatory cells, activate satellite cells. Activation of 
satellite cells, muscle progenitor cells in adult muscle, leads to their proliferation and 
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differentiation to repair the damaged muscle (Yin et al., 2013). This process of 
regenerative myogenesis is regulated by a group of transcription factors called muscle 
regulatory factors which include MyoD, Myf5, Mrf4 and Myogenin. During muscle 
regeneration, myoblasts derived from the satellite cell progenitors, fuse together to 
form multinucleated myotubes which eventually mature into myofibres, much the 
same as during developmental myogenesis (Tajbakhsh, 2009). 
1.5.1 Inflammatory response after skeletal muscle injury
One of the main roles of the inflammatory response is the phagocytosis of necrotic 
myofibres to provide an environment conducive for tissue repair, however the 
inflammatory response also functions to directly complement the myogenic program 
during muscle regeneration (Saclier et al., 2013a). The roles of macrophages in muscle 
regeneration have been extensively studied over recent years and studies have shown 
that perturbation of the inflammatory response adversely affects tissue repair (Arnold 
et al., 2007, Tidball and Wehling-Henricks, 2007). 
Macrophages are broadly classified in two categories that are referred to as M1 and 
M2 macrophages. Macrophages activated in vitro by cytokine stimulation towards M1 
or M2 phenotypes have been used in co-culture experiments to investigate their 
effects on myogenic cells. M1 pro-inflammatory macrophages aide in satellite cell 
activation and promote proliferation of myogenic precursors (Arnold et al., 2007). In 
contrast, macrophage polarisation towards an M2 anti-inflammatory phenotype at 
later stages of the regenerative process promotes myogenic differentiation and tissue 
repair (Saclier et al., 2013b). 
Many factors have been shown to regulate macrophage polarisation towards the M2 
phenotype including AMPK 1 (Mounier et al., 2013) and interleukin-10 (Deng et al., 
2012). Interleukin-10 suppresses the M1 macrophage phenotype while promoting the 
transition to the M2 macrophage phenotype (Tidball et al., 2014). A distinct 
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population of Foxp3+CD4+ muscle regulatory T cells were also shown to affect muscle 
regeneration (Burzyn et al., 2013). 
1.5.2 Satellite cell activation and regenerative myogenesis
As already mentioned, satellite cells, myogenic progenitors of adult muscle, normally 
exist in a quiescent state, however they become activated to proliferate after muscle 
injury. Satellite cell activation results in their proliferation and subsequent 
differentiation to regenerate the damaged muscle, a process which is similar to 
developmental myogenesis. 
Activated satellite cells, through their secretion of factors including MCP-1 and 
VEGF, have been shown to recruit monocytes early in the regenerative process to 
areas of damage (Chazaud et al., 2003), therefore promoting a pro-inflammatory 
environment to encourage both phagocytosis of necrotic tissue and proliferation of 
myogenic precursors. Similarly, TNF , a pro-inflammatory cytokine, promotes 
myogenic proliferation but inhibits myogenic differentiation (Alter et al., 2008). 
At later stages of muscle regeneration, interleukin-4 and interleukin-10, both anti-
inflammatory cytokines, act to promote myogenic differentiation and growth after 
muscle damage (Horsley et al., 2003, Deng et al., 2012, Heredia et al., 2013). 
1.5.3 Contribution of non satellite cell types to muscle regeneration
Recently, studies have shown that non-satellite cell types in skeletal muscle also 
contribute to muscle regeneration. These cell populations include interstitial cells 
such as fibro-adipogenic progenitors (FAPs) (Joe et al., 2010), TCF4+ fibroblasts 
(Murphy et al., 2011) and PW1+/Pax7- interstitial cells (PICs) (Mitchell et al., 2010a). 
Muscle resident FAPs proliferate after muscle injury and function to promote 
myogenesis. Their interaction with intact myofibres prevents their conversion into 
fibro-adipocytes in normal undamaged muscle (Uezumi et al., 2010), however, upon 
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muscle injury, FAPs are stimulated to promote satellite cell-mediated muscle 
regeneration (Joe et al., 2010). In muscle undergoing degeneration, such as dystrophic 
muscle at advanced stages of disease, FAPs are converted into fibro-adipocytes, which 
mediate fat deposition and fibrosis, creating an environment less conducive for muscle 
regeneration (Uezumi et al., 2011). 
The presence and function of FAPs are also regulated by macrophages (Lemos et al., 
2015). Binding of TNF , a pro-inflammatory cytokine secreted by M1 macrophages, 
to FAPs induces their apoptosis, reducing FAP cell numbers to basal levels. In 
contrast, TGF- , secreted by M2 anti-inflammatory macrophages, prevents the TNF -
mediated apoptosis of FAPs and promotes differentiation into fibroblasts. Therefore, 
interactions of FAPs with TNF  and TGF-  act to regulate FAPs during muscle 
regeneration (Lemos et al., 2015). 
PW1+ interstitial cells (PICs), are non-satellite cell muscle resident progenitors with 
myogenic potential, able to contribute to new regenerating myofibres (Mitchell et al., 
2010b). TCF4+ muscle connective tissue (MCT) fibroblasts also regulate muscle 
regeneration (Murphy et al., 2011). Tcf4 deletion in a barium chloride model of 
muscle regeneration results in premature myogenic differentiation and small 
regenerating myofibres (Murphy et al., 2011). 
1.5.4 Role of the extracellular matrix in muscle regeneration
Satellite cells reside between the ECM (basal lamina) and the sarcolemma of the 
myofibre where they interact with ECM components of the satellite cell niche such 
as collagen IV and laminin. Therefore the ECM is the environment that the 
satellite cell niche is in immediate contact with, and as such, composition of the ECM 
and its remodelling, may have profound effects on satellite cell activation as well as 
myogenic proliferation and differentiation. 
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Syndecans, a family of transmembrane proteoglycans, have been implicated in muscle 
regeneration. Syndecan-3 and Syndecan-4 are markers of satellite cells and muscle 
regeneration is inhibited with Syndecan-4 deletion (Cornelison et al., 2001), while 
deletion of syndecan-3 improves muscle regeneration and improves histopathology 
and muscle function in dystrophic mice (Pisconti et al., 2016). 
Transcriptional profiling of ECM components during muscle regeneration identified 
regulation of MMPs as well as biglycan in regenerating muscle (Goetsch et al., 2003). 
MMP3 and MMP9 were upregulated at early stages of cardiotoxin-induced muscle 
regeneration that correlate with myofibre necrosis and the pro-inflammatory immune 
response (Goetsch et al., 2003). In contrast, biglycan was upregulated at later stages 
between 2 and 7 days after injury, an observation supported by another study which 
showed increased biglycan expression by Western blot at 5 and 7 days after injury 
with barium chloride (Casar et al., 2004). Expression of MMP2 and MMP9 are 
upregulated in the cardiotoxin model of muscle regeneration (Kherif et al., 1999) and 
also after crush induced muscle regeneration (Zimowska et al., 2008). MMP10 
expression is also increased in notexin injured muscle (Bobadilla et al., 2014), as is 
MMP13 at later stages of cardiotoxin-induced muscle regeneration (Lei et al., 2013). 
Versican, a hyalectan proteoglycan and an ADAMTS5 substrate, is also expressed 
during developmental myogenesis (Carrino and Caplan, 1984). Another study from 
the same group also showed that versican synthesis is re-initiated during muscle 
regeneration in a freeze injury model in adult chick (Carrino et al., 1988), while more 
recently, Adamts5 expression was observed in developing limb muscle during fetal 
myogenesis in the mouse (McCulloch et al., 2009a). Adamts5 expression in the 
gastrocnemius muscle of the mdx mouse was decreased at three weeks, the 
approximate age at which there is an acute onset of myofibre necrosis (Grounds et al., 
2008), compared to older ages. Together, these studies suggest a potential role for 





The ECM and its remodelling have already been shown to be important for myoblast 
fusion and myogenic differentiation, as well as muscle regeneration in vivo. Most of 
the literature has investigated the expression and function of MMP family members, 
however relatively little is known about ADAMTS proteases in muscle regeneration. 
This is largely because members of the ADAMTS family were discovered much more 
recently than MMPs. Many recent studies have identified roles for ADAMTS 
proteoglycanases in multiple processes during embryonic development. Most of these 
insights have come about through the use of Adamts deficient mice. 
ADAMTS5 has been of particular interest since its identification as the major 
aggrecanase in the mouse. Two independent studies demonstrated that Adamts5 
deletion in mice prevents arthritis development in an experimental model (Stanton et 
al., 2005, Glasson et al., 2005). It is this activity of ADAMTS5 that results in aggrecan 
degradation and the subsequent cartilage erosion and loss of joint function. As a result, 
ADAMTS5 has become a major drug target for arthritis and ADAMTS5 inhibitors are 
currently in development. 
More recent studies have reported Adamts5 expression in fetal muscle development 
(McCulloch et al., 2009a). Expression of Adamts5 was also found to be decreased in 
muscle undergoing necrosis in the mdx mouse (Marotta et al., 2009), while another 
study showed increased versican expression in muscle biopsies from DMD patients, 
which was localised to fibrotic regions of the endomysium (Chen et al., 2000). 
Together, these data suggest that perturbed ADAMTS remodelling of versican may 
lead to elevated versican expression in dystrophic muscle. 
Whether ADAMTS proteolysis of versican occurs in dystrophic and/or regenerating 
muscle is currently unknown. If so, it is also unknown what the function of this 
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proteolysis might be, i.e. what the functional consequences of perturbed versican 
proteolysis in muscular dystrophy and muscle regeneration may be. 
1.6.1 Aims
The aims of this study are: 
To investigate the expression and function of Adamts5 in myoblast fusion and 
myogenic differentiation using in vitro models. 
To investigate the expression of Adamts5 and its substrates in the mdx mouse 
model. 
To investigate the expression and function of Adamts5 using the in vivo model 









C2C12 and HEK293T cells (ATCC) were grown in DMEM supplemented with 10% 
fetal bovine serum (Life Technologies) under standard conditions at 37°C and 5% CO2. 
C2C12 cells are a subclone (Blau et al., 1983) of the original C2 cell line which was 
derived from injured mouse skeletal muscle (Yaffe and Saxel, 1977). The C2C12 cell 
line is commonly used to model myoblast fusion and myogenic differentiation in 
vitro. The HEK293T cell line, derived from human embryonic kidney cells, is 
commonly used for expression of recombinant proteins (Thomas and Smart, 2005). 
C2C12 cells were not allowed to grow past 70% confluence to maintain their ability 
to differentiate by preventing spontaneous differentiation at high density. For time 
course experiments, cells were plated at 20,000 cells/cm2 and samples for RNA were 
collected at the time points shown in Figure 2.1. Cells reached approximately 80% 
confluence after 48 hours (designated as 0 hours differentiation) at which point 
medium was changed to DMEM supplemented with 2% horse serum (Life 
Technologies) to induce differentiation. Reducing the serum content of the medium 
promotes differentiation. 
 
Figure 2.1 Schematic depicting sample collection for the differentiation time course.
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2.2 siRNA and plasmid DNA transfection
C2C12 cells were plated at 16,000 cells/cm2 and transfected with siRNA the following 
day at approximately 70% confluence. Stealth RNAi siRNA (Life Technologies) was 
incubated with Lipofectamine RNAiMAX for 15 minutes and added to cells in Opti-
MEM serum free medium for 6 hours before changing medium back to standard 
growth medium. Cells were induced to differentiate 48 hours after plating by 
changing to differentiation medium (DMEM supplemented with 2% horse serum).  
Cells were either collected for RNA analysis or fixed and immunostained for desmin 
at 72 hours differentiation. Rescue experiments were done using conditioned medium 
from HEK293T cells transfected with ADAMTS5 expression vector. Rescue 
experiments were done by siRNA transfection as above and conditioned medium (1/4 
dilution) was added to differentiation medium until the end of the experiment. 
Plasmid DNA for transfection of HEK293T cells was made by bacterial transformation 
into DH5  competent cells (Invitrogen). Cells were heat shocked at 42°C for 45 
seconds and allowed to grow in 500 l LB medium for 1 hour at 37°C and shaking at 
150 rpm. Bacteria were then plated on LB-agar containing 50 g/ml ampicillin and 
grown overnight at 37°C. Bacteria were selected by growing in the presence of 
ampicillin since the pcDNA3.1 recombinant plasmids contain an ampicillin resistance 
gene for selective growth. Colonies were picked from the bacterial plate and cultured 
in 6 ml LB containing 50 g/ml ampicillin overnight for 16 hours at 37°C shaking at 
200 rpm. “Minipreps” were done to isolate the plasmid DNA from the bacterial 
cultures using PureLink Quick Plasmid Miniprep Kit (Invitrogen). Plasmid DNA 
concentration was measured using a NanoVue spectrophotometer (GE Healthcare). 
For conditioned medium, sub-confluent HEK293T cells were transiently transfected 
with ADAMTS5 (Longpre et al., 2009) or pcDNA3.1 (Invitrogen) empty vector 
control plasmid DNA using Lipofectamine 2000 (Invitrogen). Medium was changed 
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after 6 hours to serum-free DMEM medium. Conditioned medium and cell lysates 
were collected after 48 hours of culture in serum-free DMEM medium. Conditioned 
medium was collected using aseptic technique for use in rescue experiments. 
2.3 Immunocytochemistry and quantification
Cells were fixed in 4% PFA for 5 minutes, washed three times with PBS, blocked in 
5% normal goat serum for 1 hour, incubated in primary antibody (Table 2.1) overnight 
at 4°C. Cells were then washed three times with PBS, incubated with an appropriate 
Alexa Fluor secondary antibody (Invitrogen) for 1 hour, followed by three PBS 
washes. Cells were coverslipped with antifade DAPI mounting medium (Vectashield). 
Images were acquired using an IX70 microscope (Olympus).  
Table 2.1 Antibodies used for immunofluorescence on cells.
Antibody Type Source Product number Dilution 
Desmin (DE-U-10) Mouse monoclonal Sigma-Aldrich D1033 1/200 
Ki-67 (SP6) Rabbit monoclonal Thermo Fisher MA5-14520 1/100 
MF-20 Mouse monoclonal Developmental Studies 
Hybridoma Bank 
MF-20 1/10 
TCF4 (C48H11) Rabbit monoclonal Cell Signalling 2569 1/50 
Versican Rabbit polyclonal Thermo Fisher PA1-1748A 1/100 
Versican (GAG ) Rabbit polyclonal Merck Millipore AB1033 1/100 
 
For fusion index quantification, 15 images of cells immunostained for desmin were 
taken and quantified per experimental group for each independent experiment. 
Fusion index was calculated as the percentage of nuclei within myotubes divided by 
the total number of nuclei. Proliferation was measured as the proportion of Ki-67+ 
nuclei using 20 images per experimental group for each independent experiment. 
2.4 Creatine kinase activity
Cell lysates were collected in lysis buffer containing 50mM MES, 50mM Tris base, 1% 
Triton X-100 and complete protease inhibitor cocktail (Roche) and cleared by 
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centrifugation at 10,000g for 5 minutes. Creatine kinase activity was measured in the 
cell lysates using CK-NAC reagent (Thermo Fisher Scientific; cat # TR14010) as 
previously described in (Hunt et al., 2013).
2.5 Particle exclusion assay
The particle exclusion assay was used to visualise the pericellular matrix around 
C2C12 cells (Hattori et al., 2011). Glutaraldehyde fixed erythrocytes (Sigma-Aldrich; 
cat # R3378) were resuspended in PBS and pelleted by centrifugation at 1,000g for 7 
minutes at 4°C. C2C12 cells were transfected with siRNA as described above. Cells 
were trypsinised and re-plated at a density of 2,000 cells/well into 6 well plates 24 
hours after siRNA transfection. Cells were allowed to grow for another 24 hours and 
then stained with 1 M calcein AM (Sigma-Aldrich; cat # 17783) for 30 minutes in 
growth medium. Medium was changed after 30 minutes and 200 l of erythrocyte 
suspension in DMEM (108 erythrocytes/ml) was added. The erythrocytes were 
allowed to settle for 10 minutes before images were taken with an IX70 inverted 
microscope (Olympus). Bright field images were taken for the erythrocytes and 
images in the FITC channel were taken for the calcein labelled cells. Hyaluronidase 
digestion was done using 0.5 U/ml hyaluronidase from Streptomyces hyalurolyticus 
(Sigma-Aldrich; cat # H1136) in serum-free DMEM for 1 hour before the particle 
exclusion assay as a control. Hyaluronidase from S. hyalurolyticus was used because 
it specifically digests hyaluronan, while other hyaluronidases (e.g. from bovine testis) 
can also digest chondroitin sulphate. Images were analysed by our collaborators Dr 
Noriko Hattori and Prof Suneel Apte (Cleveland Clinic) to determine exclusion area 
and cell perimeter using custom, semi-automated scripts generated in Image-Pro v6.2 
(Media Cybernetics) as previously described (Hattori et al., 2011). A minimum of 23 




2.6 Mice and animal care
Adamts5-/- (The Jackson Laboratory) were obtained from Prof Amanda Fosang. 
C57Bl/6 were purchased from Walter and Eliza Hall Institute of Medical Research. 
C57Bl/10 and mdx were purchased from Animal Resources Centre (Canning Vale, 
WA, Australia). All procedures were approved by the Murdoch Children's Research 
Institute Animal Ethics Committee and carried out in strict accordance with the 
guidelines of the National Health and Medical Research Council (Australia). 
2.7 Genotyping
Adamts5-/- mice were genotyped as previously described (McCulloch et al., 2009a). 
Genomic DNA from ear clips was extracted using NaOH, heated for 10 minutes at 
100°C and neutralised with Tris buffer. GoTaq G2 Hot Start Green Master Mix 
(Promega) and the primers listed in Table 2.2 were used for the PCR reaction. PCR 
products were resolved using standard agarose gel electrophoresis. 
Table 2.2 Primers used for genotyping.
Primer Sequence 
Adamts5 – common CGCAGCTGACTGCTCTTGTGC
Adamts5 – wild-type GCATACCACTCCAAACTTAGA
Adamts5 – null GGGCCAGCTCATTCCTCCCAC
  
2.8 Isolation and culture of primary myoblast cultures
Primary myoblasts were isolated from four week old Adamts5-/- and C57Bl/6 mice 
essentially according to (Danoviz and Yablonka-Reuveni, 2012). Hind limb muscles 
including the tibialis anterior and gastrocnemius muscles were carefully dissected to 
eliminate as much connective tissue as possible from the muscle tissue. Muscle was 
minced with scissors and digested with 5 mg/ml collagenase (Worthington; cat # CLS-
1) and 1.2 U/ml dispase (Worthington; cat # NPRO) for 45 minutes at 37°C. Digested 
tissue was pelleted by centrifugation at 1,500g for 5 minutes, resuspended in growth 
medium (Ham's F-10 nutrient mix supplemented with 20% fetal bovine serum and 
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2.5 ng/ml basic fibroblast growth factor (Gibco) and filtered through a 40 m cell 
strainer. Cells were preplated for 1 hour (Rando and Blau, 1994) to allow the muscle 
connective tissue (MCT) fibroblasts to adhere. The non-adherent primary myoblasts, 
still remaining in the medium, were then plated onto culture dishes coated with 1% 
gelatin to encourage adherence to the dish and were allowed to grow. The MCT 
fibroblasts were grown in DMEM + 10% fetal bovine serum. 
Primary myoblasts were grown and expanded over two to three passages before 
plating for experiments. To induce myogenic differentiation, primary myoblasts were 
plated and allowed to grow to approximately 80% confluence. Fusion medium 
(DMEM supplemented with 5% horse serum) was used to induce differentiation 
(Springer et al., 2002). 
MCT fibroblasts were plated and allowed to grow for 24 hours before fixation. 
2.9 Induction of muscle regeneration
Notexin, a myotoxin isolated from venom of the Australian tiger snake Notechis 
scutatus, was used to induce muscle regeneration. Notexin is a phospholipase A2 
(Harris, 2003) which breaks down the plasma membrane, resulting in degeneration 
and subsequent regeneration of the muscle tissue. This is a model that is commonly 
used because it is reproducible and follows a well characterised series of events (Hardy 
et al., 2016). Tibialis anterior muscle was induced to regenerate by intramuscular 
injection of 40 l of 10 g/ml notexin (Latoxan). Mice were 12 weeks of age and were 
under anaesthetic for the procedure. 
2.10 Histology and immunostaining of cryosections
Tibialis anterior and quadriceps muscles were frozen in isopentane cooled in liquid 
nitrogen and stored at -80°C. Transverse cryosections (10 m) were cut using a 
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cryostat (Leica; CM3050 S) through the mid-belly of the muscle and mounted onto 
Superfrost plus microscope slides. 
Sections were stained with haematoxylin and eosin as follows. Slides were immersed 
in 70% ethanol for 5 seconds, distilled water for 10 seconds, Harris haematoxylin 
(ProSciTech) for 30 seconds, distilled water for 10 seconds, Scott’s tap water for 10 
seconds, 70% ethanol for 10 seconds, 1% eosin (ProSciTech) in 70% ethanol for 1 
minute, 95% ethanol for 2x 10 seconds, 100% ethanol for 2x 10 seconds before being 
cleared in xylene for 2x 1 minute. Slides were coverslipped using DPX mountant 
(Sigma-Aldrich). 
Sections were stained with x-gal as follows. Slides were fixed in 0.2% glutaraldehyde 
for 10 minutes at 4°C and washed in wash solution (0.02% NP-40, 0.01% sodium 
deoxycholate and 2mM MgCl2 in PBS) three times for 5 minutes each at room 
temperature. Slides were stained in stain solution (wash solution including 1 mg/ml 
x-gal (Roche), 5mM potassium ferricyanide and 5mM potassium ferrocyanide) 
overnight at 37°C. The following day, slides were counterstained with eosin and 
coverslipped with DPX mountant as above. 
For immunostaining, cryosections were fixed in 4% PFA for 5 minutes, washed three 
times with PBS, blocked in 5% normal goat serum for 1 hour and incubated in primary 
antibody (Table 2.3) overnight at 4°C. Slides were then washed three times with PBS, 
incubated with an appropriate Alexa Fluor secondary antibody (Invitrogen) for 1 
hour, followed by three PBS washes. Slides were coverslipped with antifade DAPI 





Table 2.3 Antibodies used for immunofluorescence on cryosections.
Antibody Type Source Product number Dilution 
Biglycan Rabbit (whole 
serum) 
Larry Fisher (NIH) LF-106 1/100 










Rabbit polyclonal Thermo Fisher 
Scientific 
PA1-1748A 1/100 
Versican (GAG ) Rabbit polyclonal Merck Millipore AB1033 1/100 
     
2.11 RNA isolation, cDNA synthesis & qPCR
Total RNA was isolated from cells using TRIzol (Life Technologies) according to the 
manufacturer’s protocol and resuspended in 30 l nuclease free water (Ambion). RNA 
was isolated from snap frozen muscle tissue by homogenisation in 1 ml TRI Reagent 
(Sigma-Aldrich) using a T10 Basic homogeniser (IKA) and adding 100 l of 1-bromo-
3-chloropropane. Samples were vortexed, incubated at room temperature for 10 
minutes and centrifuged at 12,000g for 15 minutes at 4°C. The aqueous phase 
containing the RNA was transferred to clean tubes and RNA was isolated using the 
SV Total RNA Isolation System (Promega) according to the manufacturer’s protocol 
and eluted in 40 l nuclease free water. RNA concentration was measured using a 
NanoVue spectrophotometer (GE Healthcare). cDNA was made using 1 g RNA, 
Random Primers (Promega), dNTPs (Promega) and M-MLV Reverse Transcriptase 
(Promega) according to the manufacturer’s protocol. 
qPCR was done in triplicate in a 384 well plate using GoTaq qPCR Master Mix 
(Promega) according to the manufacturer’s protocol and the primers listed in Table 
2.4. A LightCycler 480 Real-Time PCR Instrument (Roche) was used for qPCR as 
follows: pre-incubation at 50°C for 5 minutes, followed by 40 cycles of denaturation, 
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annealing and extension (95°C for 20 seconds for denaturation, 60°C for 30 seconds 
for annealing and 72°C for 30 seconds for extension). 
Table 2.4 Primers used for qPCR.















   
2.12 Western blotting
Conditioned medium and cell lysates were collected from HEK293T cells transiently 
transfected with ADAMTS5 expression construct. Conditioned medium was collected 
after 48 hours by centrifugation at 1,500g for 5 minutes. Cell lysates were collected in 
200 l lysis buffer (TBS containing 1% Triton X-100 and Roche complete protease 
inhibitor cocktail), centrifuged at 14,000 rpm for 10 minutes at 4°C and snap-frozen 
on dry ice. Samples were loaded onto 8% acrylamide (Bio-Rad) gels for SDS-PAGE, 
transferred onto PVDF membrane, blocked in 5% skim milk powder in TBS 
containing 0.1% Tween-20 (TBS-T) for 1 hour and incubated with 1/5,000 anti-myc 
antibody (Sigma-Aldrich; clone 9E10) at 4°C overnight. Membranes were washed 
three times for 5 minutes each with TBS-T, incubated with anti-mouse HRP 
conjugated secondary antibody (Dako) for 1 hour, washed three times for 5 minutes 
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each with TBS-T before detection with ECL prime reagent (GE Healthcare) according 
to the manufacturer’s instructions. 
2.13 Flow cytometry
Muscle tissue was dissected, minced with scissors and digested with 5 mg/ml 
collagenase (Worthington; cat # CLS-1) for 1 hour at 37°C. The digested tissue was 
triturated several times with a 5 ml serological pipette to shear the tissue and to ensure 
efficient cell release. Cells were pelleted by centrifugation at 1,500g for 5 minutes and 
resuspended in DMEM supplemented with 10% FBS. Digested tissue was sequentially 
filtered through 100 m, 70 m, and 40 m cell strainers. Filtered cells were again 
pelleted by centrifugation at 1,500g for 5 minutes and resuspended in 1 ml FACS 
buffer (PBS supplemented with 0.5% BSA). Cells were counted using trypan blue and 
the Countess automated cell counter (Life Technologies). 
Cells were incubated with anti-mouse 2.4G2 monoclonal antibody (BD Biosciences; 
cat # 553141) for 5 minutes at 4°C in FACS buffer to block Fc  II/III receptors followed 
by incubation with PE-Cy7 fluorescence-conjugated F4/80 antibody (Biolegend; clone 
BM8, rat IgG2a, cat # 123113) for 1 hour at 4°C. Compensation controls were also 
done and consisted of anti-rat compensation beads incubated with the antibody. Cells 
were incubated with DAPI and CountBright absolute counting beads (Life 
Technologies; cat # C36950) for the unstained control. Cells were acquired using an 
LSRFortessa X-20 flow cytometer (BD Biosciences) and data was analysed using 
FACSDiva software (BD Biosciences; version 8.0.1). 
2.14 Histology measures
Myofibre diameter was measured using digital images acquired from transverse 
cryosections immunostained for laminin. The minimal Feret’s diameter was measured 
using ImageJ software (NIH) according to the TREAT-NMD standard operating 
procedure (DMD_M.1.2.001). Neomyofibre area was measured using digital images 
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acquired from transverse cryosections immunostained for embryonic myosin 
(MyHCemb) using ImageJ software (NIH).  
2.15 Statistical analysis
Statistical analyses for data presented in Chapter 3 are as follows. For statistical 
analysis of qPCR data of multiple time points, One Way ANOVA with Tukey post hoc 
test was done using SPSS statistics software (IBM). For all other analyses two-tailed, 
paired Student's t-test was done.  
For all other chapters, Mann-Whitney tests were done using GraphPad Prism 
software (version 7.01). P < 0.05 was considered statistically significant. Data are 
expressed as mean ± SEM unless otherwise stated. 
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Chapter 3. Silencing Adamts5 decreases C2C12 myoblast






Formation of skeletal muscle involves fusion of mononucleated myoblasts into 
multinucleated myotubes or myofibres (Abmayr and Pavlath, 2012). This process is 
regulated by a group of transcription factors called muscle regulatory factors. MyoD, 
Myf5 and Mrf4 are determination factors, while myogenic differentiation into 
multinucleated cells is mainly controlled by Myogenin (Buckingham and Rigby, 
2014). 
Studies in drosophila, zebrafish and mouse models have led to the current model of 
myoblast fusion which comprises three parts: myoblast cell-cell adhesion; 
cytoskeletal-mediated invasion and resistance by the fusion competent cell and the 
founder cell, respectively; and destabilisation of the lipid bilayer membranes to 
promote fusion (Kim et al., 2015). Myoblast fusion and myogenic differentiation is 
commonly modelled in culture using the C2C12 cell line because it is a well 
characterised model and it is amenable to genetic manipulation for functional studies.  
Adamts5 was recently shown to be expressed during fetal myogenesis in the mouse 
(McCulloch et al., 2009a) implicating Adamts5 in myoblast fusion and muscle 
development. Versican, a proteoglycan substrate of ADAMTS5, is expressed and 
synthesised by myoblasts (Carrino and Caplan, 1984, Young et al., 1990). Versican 
binds to hyaluronan, another extracellular matrix component of myoblasts, which 
inhibits myoblast fusion and myogenic differentiation (Kujawa and Tepperman, 1983, 
Kujawa et al., 1986). In fact, the pericellular coat of myoblasts (composed of versican 
and a hyaluronan backbone) is lost as they form myotubes (Orkin et al., 1985) 
suggesting that extracellular matrix remodelling by proteases such as ADAMTS5 may 
be involved in the process. 
Much research has been done to examine the expression and function of hyaluronan 
but very little has been done to investigate the function of versican and its processing. 
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We hypothesised that ADAMTS5 processes versican to remodel the extracellular 
matrix thereby permitting myoblast fusion. We therefore sought to investigate the 
expression and role of Adamts5 in myogenic differentiation using the C2C12 cell line 
and siRNA silencing to study the role of Adamts5 in this model. 
The work presented in this chapter has been published in:  
Stupka, N. , Kintakas, C. , White, J. D., Fraser, F. W., Hanciu, M., Aramaki-Hattori, 
N., Martin, S., Coles, C., Collier, F., Ward, A. C., Apte, S. S. & McCulloch, D. R. (2013). 
Versican processing by a disintegrin-like and metalloproteinase domain with 
thrombospondin-1 repeats proteinases-5 and -15 facilitates myoblast fusion. J Biol 
Chem, 288, 1907-17. 





3.2.1 Myogenin expression increases as C2C12 myoblasts fuse
C2C12 cells were cultured and differentiated to collect time course samples for qPCR. 
Cells were cultured for two days in serum-rich growth medium before being induced 
to differentiate in low-serum differentiation medium (0 hour differentiation time 
point). 
qPCR for Myogenin was done to demonstrate that the C2C12 cells had undergone 
differentiation. Myogenin mRNA levels increased (Figure 3.1) with myogenic 
differentiation as expected given its role as a muscle regulatory factor in myogenic 
differentiation and myoblast fusion. 
 
Figure 3.1 Myogenin expression increases with C2C12 myogenic differentiation
qPCR was done for myogenin using three biological replicates in technical triplicate. Fold 
change was calculated using the Ct method. Ct values were normalised to cyclophilin and 
reported relative to the initial -24 hour proliferative time point. Data are mean ± SEM. * P < 
0.05, *** P < 0.001 compared to -24 hours. 
67 
 
3.2.2 Adamts5 expression increases during C2C12 differentiation
qPCR was done for the Adamts proteoglycanases which are known to process 
versican. These are Adamts1 (Sandy et al., 2001), Adamts4 (Sandy et al., 2001), 
Adamts5 (Longpre et al., 2009), Adamts9 (Somerville et al., 2003), Adamts15 
(Dancevic et al., 2013), Adamts20 (Silver et al., 2008). Adamts9 and Adamts20 levels 
were too low to be detected and therefore the data is not presented here. 
Adamts5 expression increases the most of all the Adamts proteoglycanases with 
differentiation (Figure 3.2). Levels increased 64 fold (P < 0.001) by 24 hours compared 
to the initial -24 hour proliferative time. Adamts5 expression continues to increase 
with differentiation and peaks at 4 days to 140 fold change (P < 0.001). 
Gene expression of the other Adamts proteoglycanases also increased with C2C12 
differentiation. Adamts1 and Adamts15 levels increased by a similar magnitude 
compared to the -24 hour time point. Adamts1 expression followed a similar pattern 
to Adamts5 though a smaller increase of 15 fold (P < 0.001) peak increase was seen 
(Figure 3.2A). Adamts15 levels also increased with myogenic differentiation, however 
in contrast to Adamts1 and Adamts5, expression peaked earlier at 24 hours with a 15 
fold increase (P < 0.001) before decreasing at 48 hours and then again at 72 hours 
returning to levels comparable to -24 hours (Figure 3.2D). Adamts4 expression also 
increased with differentiation (Figure 3.2B). Levels peaked at 24 hours to 54 fold 
change (P < 0.001) before decreasing at 72 hours and then increasing again at 4 days 




Figure 3.2 Expression of Adamts proteoglycanases during C2C12 differentiation.
qPCR was done for Adamts1, Adamts4, Adamts5 and Adamts15 (A-D) using three biological 
replicates in technical triplicate. Fold change was calculated using the Ct method. Ct values 
were normalised to cyclophilin and reported relative to the initial -24 hour proliferative time 




3.2.3 Versican expression and its processing increases during C2C12
differentiation
Versican expression was investigated in the C2C12 model, since it is an ADAMTS5 
substrate expressed in skeletal muscle. Versican expression increased 10 fold (P < 0.01) 
at 0 hours compared to the initial -24 hour time point where cells were still 
proliferating (Figure 3.3A). While versican levels changed slightly, its expression 
effectively maintained a 10-15 fold increase compared to the proliferative time point. 
To investigate versican localisation, C2C12 cells were immunostained for versican 
(GAG- ) and versikine (DPEAAE). The DPEAAE neo-epitope antibody specifically 
recognises the ADAMTS cleavage site (at Glu441-Ala442 and Glu1428-Ala1429 of versican 
V1 and versican V0, respectively). Therefore use of the DPEAAE antibody for 
immunostaining localises the G1-DPEAAE versikine fragment. 
Cells were immunostained after 6 and 72 hours of differentiation. Versican (GAG- ) 
is evidently localised in the ECM around myoblasts at 6 hours and also at 72 hours 
when C2C12 myoblasts are fusing (Figure 3.3B top panels; figure provided by Nicole 
Stupka). Some processed versican (DPEAAE immunostaining) can be seen around 
C2C12 myoblasts at 6 hours, however at 72 hours there is more punctate 
immunostaining localised between fusing cells (Figure 3.3B bottom panels; figure 




Figure 3.3 Versican is localised around C2C12 myoblasts and processed between fusing cells.
(A) qPCR was done for versican using three biological replicates in technical triplicate. Fold 
change was calculated using the Ct method. Ct values were normalised to cyclophilin and 
reported relative to the initial -24 hour proliferative time point. Data are mean ± SEM. * P < 
0.05, ** P < 0.01, *** P < 0.001 compared to -24 hours. (B) Cells were immunostained for 
versican (GAG- ; upper panels) and versikine (DPEAAE; lower panels) at 6 and 72 h, shown 
in green. DAPI nuclear staining shown in blue.  
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3.2.4 Adamts5 silencing inhibits C2C12 myoblast fusion
Given the large increase in Adamts5 expression through C2C12 differentiation and 
the versican processing shown by DPEAAE immunostaining, we hypothesised that 
Adamts5 would have a role in myoblast fusion. 
We used siRNA to silence Adamts5 in the C2C12 cell line by transfecting cells with 
siRNA specific for Adamts5. Two distinct siRNA oligonucleotides (si Adamts5-1 and 
si Adamts5-2) and a control siRNA were used. Cells transfected with siRNA were 
collected at 72 hours and qPCR was done to check for knockdown of Adamts5 (Figure 
3.4). Adamts5 levels were decreased to 28% (P < 0.001) with si Adamts5-1 compared 
to the control siRNA sample. Knockdown of Adamts5 was less effective with si 
Adamts5-2 where the level of Adamts5 expression was 47% of the control (P < 0.01). 
 
Figure 3.4 Adamts5mRNA levels are decreased in C2C12 cells transfected with siRNA.
C2C12 cells were transfected with either negative control siRNA (si Control) or siRNA 
specific for Adamts5 (si Adamts5-1; si Adamts5-2) and cultured until 72 hours differentiation. 
qPCR was done for Adamts5 to assess gene knockdown using three biological replicates in 
technical triplicate. Fold change was calculated using the Ct method. Ct values were 
normalised to cyclophilin and reported relative to si Control. Data are mean ± SEM. ** P < 




To investigate the role of Adamts5 in C2C12 differentiation, cells were 
immunostained with desmin after 72 hours of differentiation to analyse the amount 
of myoblast fusion when Adamts5 was silenced (Figure 3.5A). Desmin is a muscle-
specific cytoskeletal filament which is used to immunostain muscle cells. Fusion index 
of each experimental group was calculated which showed a decrease from 39% to 30% 
(P < 0.01) in si Adamts5-1 and a decrease from 39% to 33% (P < 0.05) in si Adamts5-2 
(Figure 3.5B). Myotube maturity was also calculated by quantifying the number of 
myotubes with 2-4; 5-9; or 10+ nuclei (Figure 3.5C). This showed that there is a 
decrease in the number of myotubes per field of view containing 5-9 nuclei in both 
siRNA (P < 0.01 for si Adamts5-1; P < 0.05 for si Adamts5-2) and those containing 10 or 
more nuclei (P < 0.05 for si Adamts5-1; P < 0.001 for si Adamts5-2). However there wasn’t 
a change in the proportion of myotubes containing 2-4 nuclei with Adamts5 silencing 





Figure 3.5 Silencing Adamts5 decreases C2C12 myoblast fusion and myotube maturation
(A) C2C12 cells at 72 hours differentiation were immunostained for desmin (green) and nuclei 
(red). Cells were transfected with either negative control siRNA (si Control) or siRNA specific 
for Adamts5 (si Adamts5-1; si Adamts5-2). (B) Fusion index was calculated from n=3 
independent experiments, representative images are shown in (A). Data are mean ± SEM. * P 
< 0.05, ** P < 0.01 compared to si Control. (C) Quantification of the number of nuclei within 
myotubes per field of view (FOV), representative images are shown in (A). Data are mean ± 





Other markers of differentiation were decreased. qPCR for myogenin at 72 hours was 
decreased in si Adamts5-1 to 60% the levels of si control group (P < 0.01) but there 
was no statistically significant decrease seen with si Adamts5-2. 
Creatine kinase is a muscle enzyme whose activity can be used as a marker of 
myogenic differentiation (Chamberlain et al., 1985). Creatine kinase activity, 
measured in cell lysates at 72 hours, showed a decrease in si Adamts5-1 (P < 0.001), 
however there was no change in si Adamts5-2. 
 
Figure 3.6 Adamts5 silencing decreases markers of myogenic differentiation
(A) qPCR was done for myogenin at 72 hours differentiation using n=3 independent 
experiments. Data are mean ± SEM. ** P < 0.01 compared to si Control. (B) Creatine kinase 
activity was measured in cell lysates collected at 72 hours differentiation using n=3 
independent experiments in 4 technical replicate samples. Data are mean ± SEM. *** P < 0.001 




3.2.5 Addition of ADAMTS5 returnsmyoblast fusion back to normal levels
To provide further evidence that this phenotype observed when Adamts5 was 
silenced was in fact due to Adamts5 silencing and not due to non-specific off target 
effects of the siRNA, we sought to do a rescue experiment by adding exogenous 
ADAMTS5 back to cells transfected with siRNA. 
Conditioned medium from HEK293T cells transfected with either empty vector or 
ADAMTS5 plasmid DNA expression constructs (Figure 3.7B) was used to differentiate 
cells transfected with Adamts5 siRNA. Conditioned medium was diluted 1:4 in 
differentiation medium. This experiment aimed to verify that the phenotype of the 
Adamts5 siRNA was not due to off-target effects of the siRNA. Indeed, addition of 
ADAMTS5 to cells transfected with Adamts5 siRNA restored myoblast fusion to 




Figure 3.7 ADAMTS5 restores fusion after its silencing with siRNA
(A) C2C12 cells at 72 hours differentiation were immunostained for desmin (red) and nuclei 
(blue). Cells were transfected with either negative control siRNA (si Control) or siRNA 
specific for Adamts5 (si Adamts5-1; si Adamts5-2) and then differentiated in DM with either 
ADAMTS5 or empty vector control conditioned medium. (B) Western blot of empty vector 
and ADAMTS5 conditioned medium probed with anti-myc antibody to detect ADAMTS5 in 
conditioned medium used in (A). (C) Fusion index was calculated from n=3 independent 
experiments, representative images are shown in (A). Data are mean ± SEM. *** P < 0.001 




3.2.6 Silencing Adamts5 results in extracellular matrix accumulation
Given that Adamts5 silencing impaired myoblast fusion and a recent study showed 
that Adamts5-/- dermal fibroblasts which therefore lack Adamts5 have an 
accumulation of extracellular matrix (Hattori et al., 2011), we examined whether 
there was also an increase in extracellular matrix in our model.  
Sub-confluent C2C12 transfected with si Control or si Adamts5-1 siRNA were 
fluorescently labelled with calcein AM and fixed erythrocytes were added to the 
cultures for the particle exclusion assay in order to visualise the ECM (Figure 3.8A). 
The ECM around cells exclude the erythrocyte particles showing a void area where 
there is ECM which can be quantified.  
An increase in pericellular coat (ECM) around cells is seen in si Adamts5-1 cells 
compared to si Control (Figure 3.8A). Furthermore, si Adamts5-1 cells were also 
incubated with hyaluronidase from Streptomyces hyalurolyticus prior to exclusion 
assay. There was a decrease in matrix exclusion area around these cells, comparable 
to si Control cells. Hyaluronidase digestion was done as a control to show that matrix 
exclusion area decreases when the hyaluronan backbone of the matrix is digested. 
Treatment with hyaluronidase reduced the exclusion area as expected (Figure 3.8A). 
Quantification of the exclusion area shows that there is a 2.8 fold increase in exclusion 
area in si Adamts5-1 cells compared to si Control (Figure 3.8B, P < 0.001). The same 
is also true when exclusion area is normalised to cell perimeter (Figure 3.8C, P < 0.001) 




Figure 3.8 Extracellular matrix around C2C12 cells is increased when Adamts5 is silenced
(A) C2C12 cells transfected with either negative control siRNA (si Control) or siRNA specific 
for Adamts5 (si Adamts5-1) were cultured at sub confluent density for the particle exclusion 
assay. Cells were fluorescently labelled with calcein AM (green) and fixed erythrocytes were 
added. The pericellular matrix around the cells excludes the erythrocytes. Cells transfected 
with si Adamts5-1 were also treated with hyaluronidase which results in a reduction in matrix 
exclusion. (B) Exclusion area was quantified from n=3 independent experiments, 
representative images are shown in (A). Data are mean ± SEM. *** P < 0.001 compared to si 
Control. (C) The exclusion area / cell perimeter ratio was quantified from the same images as 




Adamts5 expression was recently reported in developing skeletal myoblasts 
(McCulloch et al., 2009a) implying a role for Adamts5 in myogenic differentiation. 
The purpose of the present study was to further investigate Adamts5 expression and 
its role in myoblast fusion with a focus on its proteolytic activity towards versican. 
Results from this chapter demonstrated that Adamts5 expression increased with 
myogenic differentiation. Expression and processing of the ADAMTS5 substrate 
versican also increased during C2C12 differentiation. Further, silencing Adamts5 by 
siRNA resulted in decreased myoblast fusion and myotube maturity which was 
restored to control levels with the addition of exogenous ADAMTS5. We also showed 
that cells exhibited an accumulation of extracellular matrix when Adamts5 is silenced 
which impairs cell-cell contact and subsequent myoblast fusion. 
The data presented in this chapter which shows an increase in Adamts5 expression 
with myogenic differentiation supports the observation that Adamts5 is expressed 
during fetal myogenesis (McCulloch et al., 2009a). Expression of the other Adamts 
proteoglycanases investigated was also increased with myogenic differentiation. The 
pattern of Adamts expression (Figure 3.2), and particularly for Adamts5, was similar 
to the changes in expression seen for Myogenin (Figure 3.1) again suggesting an 
association for Adamts5 with myogenic differentiation since the role of Myogenin is 
mainly to co-ordinate myoblast fusion. 
Versican, a proteoglycan substrate of the Adamts proteoglycanases, is expressed and 
synthesised during myogenic differentiation. We showed its expression also increased 
with myogenic differentiation. Further, we also showed that versican processing 
(DPEAAE immunostaining) specific for processing by Adamts proteoglycanases 
(Nandadasa et al., 2014) increased at 72 hours and was localised between fusing 
myotubes. Together, this data implies a potential role for ADAMTS5 proteolytic 
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activity to remodel the extracellular matrix for myoblast fusion and myogenic 
differentiation. Myoblasts have an extracellular matrix composed of versican bound 
to hyaluronan (among other things) which is lost as they fuse into multinucleated 
myotubes (Orkin et al., 1985) suggesting that extracellular matrix remodelling by 
proteases such as ADAMTS5 may be involved in the process. To date much of the 
research effort in this area has been focussed on investigating the expression and 
function of hyaluronan, which inhibits myoblast fusion and myogenic differentiation 
(Kujawa and Tepperman, 1983, Kujawa et al., 1986), however very little is known 
about versican and its processing during myoblast fusion and myogenic 
differentiation. 
Silencing Adamts5 resulted in decreased myoblast fusion and myogenic 
differentiation, as demonstrated by the decreases in fusion index, myogenin mRNA 
levels and creatine kinase activity. Metalloproteinases such as the MMP and ADAMTS 
families have endogenous inhibitors such as TIMP3 (tissue inhibitor of 
metalloproteinase 3). TIMP3 inhibits ADAMTS5 as well as other metalloproteinases 
and its function has previously been studied in myogenic differentiation (Liu et al., 
2010). TIMP3 mRNA and protein levels were both decreased during C2C12 
differentiation after 24 and 48 hours of differentiation (Liu et al., 2010), correlating 
with increased Adamts5 expression (Figure 3.2C). It therefore seems that TIMP3 
levels may decrease to permit ADAMTS5 to function. In the same study, 
overexpression of TIMP3 by adenovirus infection of C2C12 cultures resulted in 
decreased myoblast fusion, similar to the phenotype seen when Adamts5 was silenced 
(Figure 3.5). While the decrease in fusion with TIMP3 overexpression may in part be 
due to TIMP3 inhibiting ADAMTS5, its inhibition of ADAM17 (TNF  converting 
enzyme) seems to have the main effect since fusion was restored to control levels 
when cells overexpressing TIMP3 were also treated with TNF  (Liu et al., 2010). 
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Decreasing chondroitin sulphate levels, the GAG component of versican, by 
treatment with chondroitinase ABC, increased fusion index (Mikami et al., 2012). In 
contrast, by silencing Adamts5 in this chapter, there could conceivably be an increase 
in versican due to reduced proteolysis, and therefore also a potential increase in 
chondroitin sulphate, potentially accounting for the decreased fusion index seen here. 
Furthermore that study also knocked down C4ST-1 (chondroitin 4-O-
sulfotransferase-1) which is a major chondroitin sulphate biosynthetic enzyme and 
also showed increased fusion index in C2C12 cells (Mikami et al., 2012).  
Rescue experiments were done by adding ADAMTS5 to cells transfected with siRNA 
to verify that the phenotype observed when Adamts5 was silenced was not due to 
non-specific off target effects of the siRNA. Cells were differentiated in either 
ADAMTS5 or empty vector control conditioned medium. This experiment showed 
that fusion was returned to control levels when ADAMTS5 levels were restored by 
addition of conditioned medium and therefore provided more evidence that the 
decrease in fusion observed with silencing of Adamts5 was indeed due to specific 
effects of the siRNA. 
Given that versican was expressed in C2C12 cells and that its processing (DPEAAE 
immunostaining) was localised around fusing myoblasts, we hypothesised that 
ADAMTS5 was remodelling versican and that the deficiency of Adamts5 due to 
siRNA silencing resulted in an accumulation of versican around the cells which 
prevented fusion. Indeed, we showed that silencing Adamts5 resulted in extracellular 
matrix accumulation in agreement with a study that showed extracellular matrix 
accumulation around dermal fibroblasts isolated from Adamts5-/- mice (Hattori et al., 
2011). 
We therefore propose the mechanism through which ADAMTS5 remodels versican 
in myoblast fusion is: versican is synthesised and secreted into the ECM; ADAMTS 
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proteoglycanases remodel versican which allows for myoblast fusion to proceed to 
form multinucleated myotubes (Kim et al., 2015). 
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Chapter 4. Adamts5 is expressed by muscle connective tissue





As well as immortalised cell lines, such as the C2C12, primary myoblast cultures are 
also used as a model to investigate the mechanisms of myoblast fusion and myogenic 
differentiation (Danoviz and Yablonka-Reuveni, 2012). Although it is more 
commonly used than primary cultures, owing to its amenability and availability, the 
C2C12 cell line has its limitations. Due to the nature of the gene silencing approach 
used in Chapter 3, I was unable to investigate the effects of Adamts5 silencing on 
proliferation and how that may affect subsequent myogenic differentiation. Using 
primary myoblasts isolated from Adamts5-/- and wild-type (C57Bl/6) mice enable 
such questions to be addressed. Furthermore, the Adamts5-/- mice allow for Adamts5 
expression to be investigated due to the insertion of a LacZ reporter cassette within 
the Adamts5 locus (McCulloch et al., 2009a). Isolation of primary myogenic cultures 
and enrichment by preplating (Richler and Yaffe, 1970, Rando and Blau, 1994) is 
advantageous because it permits the isolation of two separate cell populations: primary 
myoblasts and muscle connective tissue (MCT) fibroblasts. 
Therefore the aims of this chapter are to use primary cultures isolated from skeletal 
muscle of Adamts5-/- and wild-type mice: 
To determine the cellular origin of Adamts5 in muscle. 
To investigate the role of Adamts5 in myogenic proliferation and 





4.2.1 Adamts5 is not expressed by primary myoblasts
Primary myoblasts were isolated from four week old mice and enriched for myoblasts 
by preplating (Richler and Yaffe, 1970, Rando and Blau, 1994). The suspension 
obtained after enzymatic digestion of the tissue was briefly plated onto culture dishes, 
allowing the more adherent MCT fibroblasts to adhere, while the primary myoblasts 
remained in suspension. The myoblasts were then removed and cultured in separate 
culture dishes, therefore permitting the isolation of the two separate cell populations. 
Primary myoblasts were cultured to investigate whether they express Adamts5. LacZ 
(Adamts5) reporter activity was used to investigate Adamts5 expression. The 
Adamts5-/- mouse, created by insertion of a nuclear-targeted LacZ reporter cassette 
into the Adamts5 locus (McCulloch et al., 2009a), enables Adamts5 reporter activity 
(McCulloch et al., 2009a, Wylie et al., 2012, Hattori et al., 2011). 
Absence of LacZ reporter activity in primary myoblasts (Figure 4.1A) demonstrates 
they do not express Adamts5. To confirm the myogenic nature of the cells, cultures 
were immunostained for the intermediate filament desmin (Rando and Blau, 1994) 
(Figure 4.1B). Phase contrast and desmin immunostaining shows the characteristic 
small and rounded morphology of myoblasts (Springer et al., 2002, Danoviz and 




Figure 4.1 Adamts5 is not expressed by desmin+ primary myoblasts
Absence of LacZ (Adamts5) reporter activity together with desmin immunostaining 
demonstrate that primary myoblasts do not express Adamts5. (A) Primary myoblasts were 
stained with x-gal (left: phase contrast image; right: brightfield image). Phase contrast (left) 
and brightfield (right) are the same field of view. (B) Left: Phase contrast image of primary 
myoblasts. Right: Primary myoblasts were immunostained for desmin (green) and nuclei 
(blue). Phase contrast (left) and immunostaining (right) are the same field of view. 
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4.2.2 Fusion of primary myoblasts is not affected by Adamts5 levels
Given that Adamts5 is not expressed by primary myoblasts, I therefore hypothesised 
that there would not be an effect on fusion of Adamts5-/- primary myoblasts. To test 
this hypothesis, primary myoblasts were cultured and induced to differentiate in 
culture medium containing low levels of serum (Springer et al., 2002). Two days after 
differentiation, cultures were fixed and immunostained for sarcomeric myosin (MF-
20) (Figure 4.2). Fusion index was calculated from 10 fields of view per experiment for 
two independently isolated cultures per genotype and shown not to be affected by 





Figure 4.2 Adamts5 levels do not affect fusion of primary myoblasts
(A) Primary myoblasts were differentiated for two days and immunostained for myosin (MF-
20; green) and nuclei (blue). (B) Fusion index was calculated as the percentage of nuclei 
contained within MF-20+ myotubes containing >2 nuclei from n=2 independent experiments. 
Representative images are shown in (A). Data are mean ± SEM. 
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4.2.3 Adamts5 is expressed by muscle connective tissue fibroblasts
Whether Adamts5 is expressed by MCT fibroblasts, was investigated next, since 
fibroblasts are the major ECM-producing cells. Furthermore, mouse dermal 
fibroblasts are known to express Adamts5 (Hattori et al., 2011).  
LacZ reporter activity in MCT fibroblasts (Figure 3.2A) demonstrates their expression 
of Adamts5. In addition to their characteristic morphology (large, flat cells) (Springer 
et al., 2002), TCF4 immunostaining (Figure 3.2B) was also done to confirm them as 




Figure 4.3 Adamts5 is expressed by TCF4+ muscle connective tissue fibroblasts.
LacZ (Adamts5) reporter activity together with TCF4 immunostaining demonstrate that MCT 
fibroblasts primary myoblasts express Adamts5. (A) MCT fibroblasts were stained with x-gal 
(left: phase contrast image; right: brightfield image). Phase contrast (left) and brightfield 
(right) are the same field of view. (B) Left: Phase contrast image of MCT fibroblasts. Right: 
MCT fibroblasts were immunostained for TCF4 (green) and nuclei (blue). Phase contrast (left) 
and immunostaining (right) are the same field of view.  
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4.2.4 Fibroblast proliferation is not affected by Adamts5 levels
Given that MCT fibroblasts express Adamts5, but myoblasts do not, I sought to 
investigate whether proliferation is affected in Adamts5-/- MCT fibroblasts. To do so, 
MCT fibroblasts were cultured for 24 hours and immunostained for Ki-67 (Figure 3.3), 
a commonly used marker of cell proliferation (Arnold et al., 2007, Abou-Khalil et al., 
2009). There was no statistically significant difference in proliferation (P > 0.05), 
measured as the proportion of Ki-67+ nuclei (Figure 3.3). 
 
Figure 4.4 Adamts5 levels do not affect fibroblast proliferation
(A) Primary muscle connective tissue fibroblasts isolated from C57Bl/6 and Adamts5-/- mice 
were immunostained for Ki-67 (pink) and nuclei (blue). (B) Proliferation was calculated as 
the percentage of Ki-67+ cells from n=3 independent experiments. Representative images are 




Due to the limitations of the C2C12 cell line, the data presented in this chapter used 
primary cultures isolated from skeletal muscle, to further investigate the expression 
and function of Adamts5 in myoblast fusion and myogenic differentiation. 
Furthermore, this approach enabled the isolation of separate myoblast and MCT 
fibroblast cell populations (Danoviz and Yablonka-Reuveni, 2012, Springer et al., 
2002). This approach enables us to investigate expression of Adamts5 and any effects 
of its deletion on myogenic cells and MCT fibroblasts individually. 
We show that Adamts5 is not expressed by primary myoblasts, via LacZ reporter 
activity, and that deletion of Adamts5 does not affect fusion of primary myoblasts. 
Adamts5 is, however, expressed by MCT fibroblasts but its deletion does not affect 
fibroblast proliferation. Similarly, a previous study reported that mouse dermal 
fibroblasts express Adamts5 and its deletion also does not affect proliferation (Hattori 
et al., 2011). 
This data using primary myoblast cultures is in contrast to that presented in Chapter 
3 using the C2C12 cell line. In particular, Adamts5 is expressed by C2C12 cells, 
however the data presented in this chapter shows that primary myoblasts do not. It 
has been reported that the immortalised cell lines, such as the C2C12, differ in their 
biology to primary myoblasts, reviewed in (Danoviz and Yablonka-Reuveni, 2012). 
For example, while collagen VI expression was previously shown in C2C12 cells, it is 
not expressed by primary myoblasts, but instead expressed by MCT fibroblasts (Zou 
et al., 2008). Similarly, Adamts5 expression was reported in skeletal muscle tissue 
during fetal myogenesis, however it was not verified by which cell type(s) it is 
expressed within the muscle tissue (McCulloch et al., 2009a). The data presented in 
this chapter implies that MCT fibroblasts are also likely the source of Adamts5 during 
fetal myogenesis, however further investigation is required to test that hypothesis. 
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Future directions to further investigate the role of Adamts5 in a primary culture 
system could include co-culture experiments with primary myoblasts and MCT 










Adamts5 expression has been reported in developing skeletal muscle (McCulloch et 
al., 2009a), as was its differential expression in the mdx mouse in a microarray 
profiling study (Marotta et al., 2009). That study showed Adamts5 expression in the 
gastrocnemius of the mdx mouse was decreased at 3 weeks, the approximate age at 
which there is an acute onset of myofibre necrosis (Grounds et al., 2008). 
Furthermore, expression of versican, a well-characterised ADAMTS5 substrate, was 
upregulated in muscle biopsies from DMD patients compared to controls (Chen et al., 
2000). Immunostaining for versican localised its expression to fibrotic regions of the 
endomysium in DMD biopsies, while its expression was not detected by 
immunostaining in control muscle biopsies (Chen et al., 2000). 
Together, these studies imply a potential role for ADAMTS5 in ECM remodelling in 
dystrophic muscle, however the expression of Adamts5, related Adamts 
proteoglycanases and their substrates in dystrophic muscle has not been thoroughly 
reported in the literature.  
Therefore the aims of this chapter using the mdx mouse model of DMD, are: 
To investigate expression levels of Adamts5 and other Adamts 
proteoglycanases. 
To investigate Adamts5 localisation using LacZ reporter activity. 





5.2.1 Expression levels of Adamts proteoglycanases in dystrophic muscle
Quadriceps muscle tissue from mdx and C57Bl/10 wild-type control mice were 
collected at multiple key time points of pathology in the mdx mouse to characterise 
gene expression. Expression levels of Adamts5 and the other Adamts proteoglycanases 
were investigated by qPCR at 2, 3, 6, 12 and 24 weeks in both mdx dystrophic and 
C57Bl/10 wild-type control muscle. 
Adamts1 expression levels (Figure 5.1A) were not altered in mdx dystrophic muscle 
over time, however its expression was increased in wild-type muscle. Adamts1 
increased 2.7 fold (P < 0.05) in C57Bl/10 at 12 weeks, compared to 2 weeks, followed 
by a decrease of 1.5 fold (P < 0.05) at 24 weeks, compared to 12 weeks. 
Adamts4 expression (Figure 5.1B) decreased in both mdx and C57Bl/10 over time. 
Adamts4 decreased 2.6 fold (P < 0.05) in mdx at 12 weeks, compared to 2 weeks. 
Similarly, although to a greater extent, Adamts4 decreased 16 fold (P < 0.05) in 
C57Bl/10, also at 12 weeks, compared to 2 weeks. 
In contrast, Adamts5 expression (Figure 5.1C) increased over time in mdx dystrophic 
muscle, while levels in C57Bl/10 were unchanged. Adamts5 increased 2.4 fold (P < 
0.05) in mdx at 6 weeks, compared to 3 weeks of age, and levels remained elevated 
until 24 weeks. Furthermore, there were genotype differences in Adamts5 expression 
at 2 and 3 weeks of age. There were 1.6 (P < 0.05) and 2.2 (P < 0.05) fold decreases in 
the mdx compared to C57Bl/10 at 2 and 3 weeks, respectively. 
Overall, there was a trend of decreased Adamts9 expression (Figure 5.1D) in both mdx 
and C57Bl/10 with age. Adamts9 expression decreased 3 fold (P < 0.05) in mdx at 12 
weeks, compared to 2 weeks. Likewise, Adamts9 decreased 1.8 fold (P < 0.05) in 
C57Bl/10 at 6 weeks, compared to 2 weeks. 
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There was also a general trend of decreased Adamts15 expression (Figure 5.1E) in both 
mdx and C57Bl/10 muscle over time. Adamts15 decreased 1.8 fold (P < 0.05) in mdx 
at 12 weeks, compared to 2 weeks. In contrast, while there was a trend for decreased 
Adamts15 expression in C57Bl/10 over time, there were no statistically significant 
differences. 
Expression of Adamts20 (Figure 5.1F) decreased in both mdx and C57Bl/10 over time. 
Adamts20 decreased 2.6 fold (P < 0.05) in mdx at 12 weeks, compared to 2 weeks. 
There was also a similar 1.9 fold decrease (P < 0.05) in Adamts20 expression in 





Figure 5.1 Expression of Adamts proteoglycanases in mdx dystrophic muscle.
Expression levels of Adamts1, Adamts4, Adamts5, Adamts9, Adamts15 and Adamts20 (A-F) 
in quadriceps muscle from dystrophic mdx and C57Bl/10 wild-type control mice. Data is 
presented as mean relative mRNA expression normalised to Hprt and represents four 
biological replicates in technical triplicate. Error bars are SEM. * P < 0.05. 
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5.2.2 Adamts5 localisation in dystrophic muscle
LacZ (Adamts5) reporter activity was used to investigate the localisation of Adamts5 
expression in dystrophic muscle. The Adamts5-/- mouse, generated by insertion of a 
LacZ expression cassette into the Adamts5 locus, was crossed with the mdx mouse to 
generate mdx:Adamts5-/- mice. 
Transverse cryosections of mdx:Adamts5-/- quadriceps were stained with x-gal to 
reveal LacZ (Adamts5) reporter activity (Figure 3.2). LacZ activity demonstrates 
Adamts5 expression in multiple cell types in dystrophic muscle including: blood 
vessels (Figure 3.2A), regenerating myofibres (Figure 3.2B), perimysium (Figure 3.2C-
D), interstitial cells (Figure 3.2E & Figure 3.2H-I) that are most likely fibroblasts, 





Figure 5.2 Adamts5 localisation in mdx dystrophic muscle.
Nuclear lacZ (Adamts5) reporter activity (blue) reveals Adamts5 is expressed by multiple cell 
types in dystrophic quadriceps of mdx:Adamts5-/-. Arrows indicate: blood vessel (A), 
regenerating myofibres (B), perimysium (C-D), interstitial fibroblasts (E), nerve (F), 




5.2.3 Biglycan expression in dystrophic muscle
Biglycan, an ADAMTS5 substrate (Melching et al., 2006, Gendron et al., 2007), is 
expressed in skeletal muscle where it is a component of the DAPC (Bowe et al., 2000, 
Rafii et al., 2006). Furthermore, biglycan is currently being developed as a therapeutic 
for Duchenne muscular dystrophy because of its ability to improve function in 
dystrophic muscle by upregulating utrophin levels (Amenta et al., 2011). 
Biglycan expression in both mdx and C57Bl/10 was not altered at younger ages (Figure 
5.3A). Biglycan expression decreased 2.9 fold (P < 0.01) in mdx at 24 weeks, compared 
to 12 weeks. Similarly, biglycan decreased 3.1 fold (P < 0.05) in C57Bl/10 at 12 weeks, 
compared to 2 weeks. 
Transverse cryosections of mdx quadriceps were immunostained for biglycan (Figure 





Figure 5.3 Biglycan expression and its localisation in mdx dystrophic muscle.
(A) Expression levels of biglycan in quadriceps muscle from dystrophic mdx and C57Bl/10 
wild-type control mice. Data is presented as mean relative mRNA expression normalised to 
Hprt and represents four biological replicates in technical triplicate. Error bars are SEM. * P < 
0.05, ** P < 0.01. (B) Quadriceps of 12 week old mdx were immunostained for biglycan, shown 




5.2.4 Versican expression and its processing in dystrophic muscle
Versican, a well-characterised ADAMTS5 substrate, is upregulated in muscle of DMD 
patients (Chen et al., 2000). However, whether ADAMTS proteolysis of versican 
occurs in dystrophic muscle has not been reported. 
Versican expression (Figure 5.4A) decreased in both mdx and C57Bl/10 over time. 
Versican decreased 3.2 fold (P < 0.05) in mdx at 24 weeks compared to 2 weeks. In 
C57Bl/10, versican expression decreased 1.7 fold (P < 0.05) at 3 weeks compared to 2 
weeks, followed by another 3.1 fold decrease (P < 0.05) at 12 weeks, compared to 3 
weeks. 
Transverse cryosections of mdx quadriceps were immunostained for versican (GAG-
) and versikine (DPEAAE) (Figure 5.4B). The DPEAAE neo-epitope antibody 
specifically recognises the ADAMTS cleavage site (at Glu441-Ala442 and Glu1428-Ala1429 
of versican V1 and versican V0, respectively). Therefore use of the DPEAAE antibody 
for immunostaining localises the G1-DPEAAE versikine fragment.  
Versican (GAG- ) immunostaining shows its expression localised to the interstitium, 
however it is not seen in highly nucleated areas, which is characteristic of 
inflammatory regions. In contrast, versikine (DPEAAE) immunostaining is localised 





Figure 5.4 Versican expression and its localisation in mdx dystrophic muscle.
(A) Expression levels of versican in quadriceps muscle from dystrophic mdx and C57Bl/10 
wild-type control mice. Data is presented as mean relative mRNA expression normalised to 
Hprt and represents four biological replicates in technical triplicate. Error bars are SEM. * P < 
0.05. (B) Quadriceps of 12 week old mdx were immunostained for versican (GAG- ; upper 
panels) or versikine (DPEAAE; lower panels), shown in green. Laminin immunostaining is 




While differential Adamts5 expression in the mdx mouse has been reported, the 
expression of related Adamts proteoglycanases together with their substrates has not. 
Methods used to investigate the expression and localisation of Adamts 
proteoglycanases and their substrates were qPCR, LacZ reporter activity and 
immunostaining. 
Data presented in this chapter showed that there were differences in expression of 
Adamts1, Adamts5 and Adamts15 between mdx and C57Bl/10 genotypes. The 
Adamts5 expression data was of particular interest because there was no change over 
time in C57Bl/10 but its expression was altered in mdx over time. Furthermore, 
Adamts5 was decreased in mdx (compared to C57Bl/10) at 2 and 3 weeks of age, which 
correlates with the acute onset of myofibre necrosis seen in the mdx mouse (Grounds 
et al., 2008). 
Most of the data presented in this chapter replicates previously published findings by 
Marotta and colleagues, including the decreased Adamts5 expression in mdx at 3 
weeks (Marotta et al., 2009). In contrast, however, data presented in this chapter also 
reports decreased Adamts5 expression in the mdx at 3 weeks compared to age-
matched C57Bl/10, while Marotta and colleagues did not. This is likely attributed to 
differences in experimental approach. Marotta and colleagues used semi-quantitative 
RT-PCR and report fold changes based on densitometry of PCR amplicon bands 
(Marotta et al., 2009), whereas we used qPCR which is more sensitive. Furthermore, 
we used quadriceps muscle, while Marotta and colleagues used tissue from the medial 
gastrocnemius, which may also contribute to the differences seen.  
While Adamts5 expression in developing skeletal muscle had been previously 
reported (McCulloch et al., 2009a), nothing is known about its cellular localisation in 
dystrophic muscle. LacZ reporter activity was used to identify the sources of Adamts5 
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in dystrophic muscle of mdx:Adamts5-/- mice. Expression was localised to blood 
vessels, regenerating myofibres and interstitial cells. Expression of Adamts9 has 
previously been shown in endothelial cells (Koo et al., 2010), while Adamts5 
expression in dermal fibroblasts (Hattori et al., 2011) and MCT fibroblasts (Chapter 4) 
has also been reported. This suggests the interstitial cells expressing Adamts5 are 
likely to be MCT fibroblasts, however this needs to be confirmed by dual 
immunostaining for a marker such as TCF4. 
Primary myoblasts do not express Adamts5 (chapter 4), however it is not known 
whether freshly sorted quiescent satellite cells do express Adamts5. Therefore it is 
unknown whether the Adamts5 expression observed in regenerating myofibres 
(Figure 3.2B) may be due to expression by a myogenic precursor (of satellite cell 
lineage); or by PW1+ interstitial cells (PICs), which are non-satellite cell muscle 
resident progenitors with myogenic potential, and able to contribute to new 
regenerating myofibres (Mitchell et al., 2010b). 
Biglycan immunostaining in 12 week mdx was localised to punctate regions of the 
perimysium, while its localisation was previously reported around the periphery of 
myofibres in younger mdx mice (Bowe et al., 2000). Unfortunately, however, a neo-
epitope antibody to detect ADAMTS proteolysis of biglycan has not been developed, 
therefore this could not be investigated here. 
Versican expression was previously shown to be increased in muscle biopsies of DMD 
patients, localised to fibrotic regions of the endomysium (Chen et al., 2000). In 
contrast, we did not see increased versican expression in mdx dystrophic muscle, 
compared to C57Bl/10, at any of the time points examined here. This is likely due to 
the more mild nature of pathology in the mdx mouse (Partridge, 2013). 
Immunostaining for versican in mdx dystrophic muscle was, however, localised to the 
endomysium, in agreement with the aforementioned finding in DMD muscle biopsies. 
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In order to test whether increased versican expression correlates with severe muscle 
fibrosis, there are multiple methods which can be used to induce fibrosis (Pessina et 
al., 2014) and to exacerbate the pathology of the mdx mouse to more closely resemble 
DMD. For example, mdx mice which are exercised (chronic treadmill exercise) for a 
period of up to 3 months, induces fibrosis comparative to that seen in human DMD 
muscle (Pessina et al., 2014). Such an approach could be used to test whether versican 
expression is increased in fibrotic mdx dystrophic muscle. This model could also be 
used to investigate Adamts5 (LacZ reporter activity) and versikine (DPEAAE 
immunostaining) localisation in a more fibrotic model, of more relevance to DMD. 
Of particular interest is the localisation of the ADAMTS-generated versikine 
fragment, revealed by DPEAAE immunostaining, which has not been previously 
reported in dystrophic muscle. Versikine was localised to blood vessels and punctate 
interstitial staining suggesting either fibroblasts or satellite cells. Interestingly, this 
localisation is similar to that of the LacZ (Adamts5) reporter activity also presented in 
this chapter, which was observed in similar areas, indicating the ADAMTS processing 
of versican (versikine) may be due to Adamts5, since their expression appear to co-
localise. In order to confirm co-localisation, future work would require double 
immunostaining for versikine and -galactosidase (an alternative approach used to 
detect LacZ reporter activity). 
Furthermore, a recent study identified ADAMTS5 as a therapy-responsive serum 
biomarker (Coenen-Stass et al., 2015). The study found that ADAMTS5 was increased 
in serum of mdx mice compared to C57Bl/10 wild type controls. They also restored 
dystrophin levels in mdx mice with exon skipping and showed that serum ADAMTS5 
levels decreased towards wild type levels, showing that ADAMTS5 may be potentially 
used as a clinical biomarker. Furthermore, ADAMTS5 was measured in patient serum 
and showed increased levels in DMD patient serum compared to control (Coenen-
Stass et al., 2015). Whether Adamts5 may play a role in muscular dystrophy is yet to 
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be seen and further investigations using the mdx:Adamts5-/- cross are required, and 




Chapter 6. Adamts5 is expressed by regenerating muscle but





Adamts5 is expressed by C2C12 cells and MCT fibroblasts but is not expressed by 
primary myoblasts (Chapters 3 & 4). The overall aim of this chapter is to further 
investigate the role of Adamts5 using an in vivo model of muscle regeneration. 
Intramuscular injection of notexin, a myotoxin, is a commonly used experimental 
model of muscle regeneration in vivo. This model was used since it is reproducible 
and follows a well characterised series of events (Hardy et al., 2016). 
The aims of this chapter using notexin-induced muscle regeneration are: 
To investigate expression levels of Adamts5 and other Adamts 
proteoglycanases. 
To investigate Adamts5 localisation using LacZ reporter activity. 
To investigate expression levels of key ADAMTS5 substrates. 
To investigate the effects of Adamts5 deletion on the inflammatory and 





6.2.1 Expression levels of Adamts proteoglycanases in regenerating
muscle
We first wanted to investigate expression of Adamts5 and the other Adamts 
proteoglycanases in muscle induced to regenerate by notexin injury. C57Bl/6 mice 
were injected with notexin in the TA muscle. TA muscle was collected at 1, 3, 5, 7 
and 14 days after injury as well as an uninjured age matched control. 
Haematoxylin and eosin staining was done to examine the histology of the injured 
tissue at various times after injury and to correlate changes in gene expression levels 
to the stage of regeneration by histology (Figure 5.1). Uninjured muscle is shown as a 
reference for normal muscle histology (Figure 5.1A). Note the regular appearance of 
myofibres with nuclei located at the periphery of myofibres. Lightly coloured necrotic 
myofibres and an increase in nuclei around the myofibres, indicative of the early 
inflammatory response, can be seen 1 day after notexin injury (Figure 5.1B). Three 
days after notexin injury, the tissue is highly nucleated due to the increase in immune 
cells as part of the inflammatory response (Figure 5.1C). Small regenerating myofibres 
are seen 5 days after notexin injury. The regenerating myofibres have centrally 
located nuclei, characteristic of newly regenerating myofibres (Figure 5.1D). 
Regenerative myogenesis continued to progress 7 days after injury with continued 
fusion of myocytes resulting in increased size of myofibres (Figure 5.1E). TA muscle 
continued regeneration 14 days after notexin injury with the size of the regenerating 





Figure 6.1 Histology of TA muscle after notexin induced muscle regeneration.
Haematoxylin and eosin staining of TA (tibialis anterior) muscle after notexin-induced muscle 
regeneration. (A) Regular appearance of myofibres and peripheral nuclei represent normal 
muscle histology in uninjured muscle. (B) Lightly coloured necrotic myofibres and the early 
inflammatory response is demonstrated by nuclei infiltrating the muscle 1 day after induction 
of regeneration. (C) Extensive infiltration of inflammatory cells 3 days after induction of 
regeneration. (D) Formation of neomyofibres with centralised nuclei 5 days after induction 
of regeneration. (E) Neomyofibres continue to regenerate and increase in size 7 days after 
induction of regeneration. (F) Regenerating myofibres with persistent centralised nuclei 
continue to regenerate and increase in size 14 days after induction of regeneration. 
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Adamts1 expression levels (Figure 6.2A) decreased 5.9 fold (P < 0.05) at 3 days 
compared to 1 day but otherwise remained unchanged until 14 days after notexin-
induced muscle regeneration. Expression of Adamts4 (Figure 6.2B) increased 13.3 fold 
(P < 0.05) at 1 day compared to uninjured, followed by a 2.3 fold decrease (P < 0.01) 
at 7 days compared to 3 days after notexin-induced muscle regeneration. Adamts5 
expression (Figure 6.2C) decreased 2.6 fold (P < 0.01) at 3 days compared to levels at 
1 day after notexin-induced muscle regeneration. Adamts9 expression levels (Figure 
6.2D) increased 3.4 fold (P < 0.05) at 1 day compared to the uninjured control, 
followed by a 9.6 fold (P < 0.05) decrease at 3 days, at which point Adamts9 expression 
remained decreased until 14 days after notexin-induced muscle regeneration. 
Adamts15 expression (Figure 6.2E) remained unchanged except for a 2.6 fold increase 
(P < 0.05) at 14 days compared to 7 days after notexin-induced muscle regeneration. 
Expression of Adamts20 (Figure 6.2F) decreased 2.3 fold (P < 0.05) at 1 day compared 
to uninjured, followed by a 10 fold increase (P < 0.01) in expression at 7 days compared 





Figure 6.2 Expression of Adamts proteoglycanases after notexin induced muscle
regeneration.
Expression levels of Adamts1, Adamts4, Adamts5, Adamts9, Adamts15 and Adamts20 (A-F) 
in TA (tibialis anterior) muscle after notexin-induced muscle regeneration. Uninj = uninjured 
TA muscle from age-matched mice. Data is presented as mean relative mRNA expression 
normalised to Hprt and represents four biological replicates in technical triplicate. Error bars 
are SEM. * P < 0.05, ** P < 0.01.  
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6.2.2 Adamts5 localisation in regenerating muscle
LacZ (Adamts5) reporter activity was used to investigate the localisation of Adamts5 
expression in TA muscle after notexin-induced muscle regeneration. The Adamts5-/- 
mouse, generated by insertion of a LacZ expression cassette into the Adamts5 locus, 
was used to localise Adamts5 using the notexin model of muscle regeneration. 
Transverse cryosections of Adamts5-/- TA muscle induced to regenerate were stained 
with x-gal to reveal LacZ (Adamts5) reporter activity (Figure 3.2). LacZ activity 
demonstrates Adamts5 expression in multiple cell types in regenerating muscle 
including interstitial cells, likely to be fibroblasts, (Figure 3.2A-B & Figure 3.2E-I), 
blood vessels (Figure 3.2B) and potentially satellite cells (Figure 3.2B & Figure 3.2E-
G). Most cells in inflammatory regions at early stages of regeneration do not express 
Adamts5 (Figure 3.2C-D), while Adamts5 expression is seen in interstitial cells, again 
likely to be fibroblasts and/or satellite cells, when myofibres are regenerating (Figure 
3.2E-G). Expression of Adamts5 was also seen in small regenerating myofibres (Figure 
3.2F). At later stages of regeneration, expression was seen in interstitial cells (Figure 
3.2H), however expression was not seen in interstitial cells surrounding larger 





Figure 6.3 Adamts5 localisation after notexin induced muscle regeneration.
Nuclear lacZ (Adamts5) reporter activity (blue) reveals Adamts5 is expressed by multiple cell 
types in the TA muscle of Adamts5-/- after notexin-induced muscle regeneration. Arrows 
indicate: interstitial fibroblasts (A), blood vessel, perimysium and interstitial fibroblasts 
and/or satellite cells (B), fibroblasts in inflammatory regions (C-D), interstitial fibroblasts 
and/or satellite cells (E), regenerating myofibre and interstitial fibroblasts and/or satellite cells 
(F), interstitial fibroblasts and/or satellite cells (G), interstitial cells (H), interstitial cells (I). 




6.2.3 Expression levels of ADAMTS5 substrates in regenerating muscle
Expression levels of ADAMTS5 proteoglycan substrates were also investigated at 
various time points after notexin-induced muscle regeneration. Biglycan expression 
(Figure 6.4A) was relatively low in uninjured control but steadily increased as muscle 
regeneration progressed. There was a 2 fold (P < 0.05) increase in biglycan expression 
at 1 day compared to uninjured followed by a 1.6 fold increase (P < 0.05) at 3 days and 
another 1.6 fold increase (P < 0.01) at 5 days after notexin-induced muscle 
regeneration. Biglycan expression levels remained unchanged thereafter until 14 days 
after notexin-induced muscle regeneration. Versican expression levels (Figure 6.4B) 
also increased 7.8 fold (P < 0.05) at 1 day followed by a decrease at 3 days after notexin-
induced muscle regeneration. There was a slight 1.3 fold increase (P < 0.05) at 5 days 
compared to 3 days after which expression levels remained steady until 14 days after 




Figure 6.4 Expression of ADAMTS5 substrates after notexin induced muscle regeneration.
Expression levels of biglycan (A) and versican (B) in TA (tibialis anterior) muscle after 
notexin-induced muscle regeneration. Uninj = uninjured TA muscle from age-matched mice. 
Data is presented as mean relative mRNA expression normalised to Hprt and represents four 




6.2.4 The inflammatory response after notexin induced muscle
regeneration is not affected by Adamts5 deletion
Flow cytometry was used to investigate potential changes in the inflammatory 
response in Adamts5-/- mice at an early stage of muscle regeneration. TA muscle was 
used 3 days after notexin-induced muscle regeneration, to investigate the proportion 
of F4/80+ inflammatory cells, which was not affected by Adamts5 deletion (Figure 
6.5). 
 
Figure 6.5 Adamts5 deletion does not affect the proportion of F4/80+ cells 3 days after
notexin induced muscle regeneration.
The percentage of F4/80+ cells was determined by flow cytometry in regenerating muscle 3 
days after notexin-induced muscle regeneration. Data are mean ± SEM and represent n=3 




Inflammatory markers were also analysed by qPCR. Expression of Emr1, the 
transcript for the F4/80 protein, was investigated after notexin-induced muscle 
regeneration (Figure 6.6A). No significant differences between genotype were seen, 
although increased expression was noted in the early stages of regeneration, 
particularly at 3 and 5 days after notexin-induced muscle regeneration, coinciding 
with peak periods of inflammation. 
Interleukin-10 (Il-10) expression was also investigated since it is a cytokine involved 
in the shift of inflammatory response from the initial Th1 cytokine mediated pro-
inflammatory to the subsequent Th2 cytokine mediated anti-inflammatory phase 
(Deng et al., 2012). There were also no significant genotype differences in Il-10 
expression, suggesting that there are no differences in macrophage polarisation in the 
absence of Adamts5 (Figure 6.6B). 
 
Figure 6.6 Inflammatory markers are not affected by Adamts5 deletion after notexin induced
muscle regeneration.
Expression levels of (A) Emr1 (F4/80 transcript) and (B) Il-10 in TA (tibialis anterior) muscle 
of C57Bl/6 and Adamts5-/- mice after notexin-induced muscle regeneration. Uninj = uninjured 
TA muscle from age-matched mice. Data is presented as mean relative mRNA expression 
normalised to Hprt and represents four biological replicates in technical triplicate. Error bars 
are SEM.  
121 
 
6.2.5 Early stages of myogenesis after notexin injury are not affected by
Adamts5 deletion
Transverse cryosections were immunostained for embryonic myosin (MyHCemb) to 
investigate whether Adamts5 deletion affected formation of newly regenerating 
myofibres at early stages of myogenesis. MyHCemb is the myosin isoform specifically 
expressed by muscle fibres during embryonic development and also those undergoing 
muscle regeneration (Schiaffino et al., 2015). Its expression is down-regulated as 
regeneration progresses and is replaced by adult myosin isoforms, therefore it can be 
used to effectively identify early regenerating myofibres. Neomyofibre area measured 
and quantified 5 days after notexin injury showed no difference (P > 0.05) between 






Figure 6.7 Adamts5 deletion does not affect the size of newly regenerating myofibres 5 days
after notexin induced muscle regeneration.
(A) TA muscle of C57Bl/6 and Adamts5-/- mice 5 days after notexin-induced muscle 
regeneration was immunostained for embryonic myosin (MyHCemb; green) and nuclei 
counterstained with DAPI (blue). (B) Quantification of MyHCemb+ neomyofibre area shows 
no difference in mean neomyofibre area 5 days after notexin-induced muscle regeneration. 




Myogenic markers were also investigated by qPCR to examine whether Adamts5 
deletion affected myogenesis at other time points. Myh3 (embryonic myosin 
transcript) shows no differences in expression between genotypes (Figure 5.3A). 
Increased Myh3 expression was seen for both genotypes at 3 and 5 days after notexin-
induced muscle regeneration compared with the uninjured control, consistent with 
its known expression in regenerating muscle. Myogenin expression was also not 
affected by Adamts5 deletion although its expression also increased at 3 and 5 days 
after notexin-induced muscle regeneration (Figure 5.3B). 
 
Figure 6.8 Myogenic markers are not affected by Adamts5 deletion after notexin induced
muscle regeneration.
Expression levels of (A) Myh3 (MyHCemb transcript) and (B) Myogenin in TA (tibialis 
anterior) muscle of C57Bl/6 and Adamts5-/- mice after notexin-induced muscle regeneration. 
Uninj = uninjured TA muscle from age-matched mice. Data is presented as mean relative 
mRNA expression normalised to Hprt and represents four biological replicates in technical 
triplicate. Error bars are SEM.  
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6.2.6 Myofibre size is not affected by Adamts5 deletion at late stages of
notexin induced regeneration
TA muscle was examined 14 days after notexin-induced muscle regeneration to assess 
myofibre size. Cryosections were immunostained for laminin (to delineate myofibre 
borders) and myofibre diameter was quantified. No difference in myofibre diameter 
(P > 0.05) was seen 14 days after notexin injury (Figure 6.9). Furthermore, there was 
no difference (P > 0.05) in myofibre size in uninjured TA demonstrating no net change 





Figure 6.9 Adamts5 deletion does not affect myofibre size 14 days after notexin induced
muscle regeneration.
(A) TA muscle of C57Bl/6 and Adamts5-/- mice 14 days after notexin-induced muscle 
regeneration was immunostained for laminin (red) and nuclei counterstained with DAPI 
(blue). (B) Quantification of myofibre diameter shows no difference in mean myofibre 
diameter 14 days after notexin-induced muscle regeneration (14d). There was also no 
difference in mean myofibre diameter of uninjured TA muscle from age-matched mice (uninj) 





Adamts5 localisation was demonstrated in regenerating muscle of Adamts5-/- using 
LacZ reporter activity. Adamts5 was found to be expressed by blood vessels, 
regenerating myofibres, as well as interstitial cells, likely to be MCT fibroblasts 
(Chapter 4), but potentially also satellite cells. In contrast, Adamts5 was not expressed 
by most cells in inflammatory regions at early stages of muscle regeneration. Also of 
note is the absence of Adamts5 expression from interstitial cells around larger 
regenerating myofibres, while expression is observed in interstitial cells around 
smaller regenerating myofibres. To confirm cell types expressing Adamts5, double 
immunostaining for -galactosidase and markers such as TCF4 (MCT fibroblasts) and 
Pax7 (satellite cells) is needed. 
Biglycan expression increased during muscle regeneration as has been reported 
previously. Biglycan mRNA and protein levels were transiently increased during 
muscle regeneration induced by barium chloride. Biglycan mRNA levels were 
increased at 3 and 5 days after BaCl2 injury, while biglycan protein was increased at 5 
and 7 days after injury (Casar et al., 2004). Versican expression also increased after 
notexin-induced muscle regeneration. Synthesis of versican during muscle 
regeneration in the adult chick had also been reported in the literature. Newly 
synthesised versican was detected by 35S incorporation in a freeze injury model of 
muscle regeneration in both pectoral and gastrocnemius muscle (Carrino et al., 1988). 
Adamts5 deletion did not affect the inflammatory response after muscle damage. 
Previous studies have shown that soluble biglycan (produced through processing by 
metalloproteases) is pro-inflammatory, signalling through TLR2 and TLR4 cell surface 
receptors, resulting in the synthesis of TNF-  and IL-1  (Hsieh et al., 2014). 
Therefore, if ADAMTS5 processing of biglycan released soluble biglycan, a decrease 
in soluble biglycan production would be expected in Adamts5-/-, therefore resulting 
in less of the initial pro-inflammatory response or a premature shift in macrophage 
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polarisation towards the M2 phenotype (Hsieh et al., 2014). While ADAMTS5 
processes biglycan (Melching et al., 2006, Gendron et al., 2007), it may not cleave at 
the correct amino acid sequence in order to produce the soluble form of biglycan 
which acts as a TLR ligand. Furthermore, processing of biglycan by ADAMTS5 may 
be inefficient during muscle regeneration, therefore unable to elicit a physiologically 
relevant response. In order to further investigate this, a neo-epitope antibody 
specifically recognising ADAMTS cleavage of biglycan needs to be developed. 
There was also no difference in regenerative myogenesis in Adamts5-/-. Given that 
silencing Adamts5 inhibited C2C12 myoblast fusion (Chapter 3), it may have been 
expected that muscle regeneration would be affected by Adamts5 deletion. However 
using a primary culture system, we showed that primary myoblasts do not express 
Adamts5 (Chapter 4). It must be remembered that in vivo muscle regeneration is a 
much more complex series of processes than in vitro models which only involve a 
single cell type. Previous studies have shown that ADAMTS proteoglycanases work 
cooperatively (McCulloch et al., 2009b, Enomoto et al., 2010) and therefore it is 
conceivable that a threshold of versican (or biglycan) proteolysis needs to be reached 
in order for a phenotype to be observed. As such, future studies may include inducing 
muscle regeneration in mice deficient for multiple Adamts proteoglycanases 








The extracellular matrix has been shown to be important in maintaining skeletal 
muscle homeostasis since mutations in ECM components such as collagen VI and 
laminin 2 cause muscular dystrophies. Extracellular matrix remodelling by secreted 
metalloproteases, which include members of the MMP and ADAMTS families, is 
important during embryonic development and repair of damaged tissue. Recent 
studies have identified Adamts5 expression during fetal myogenesis in the mouse 
(McCulloch et al., 2009a), while Adamts5 expression was also shown to be decreased 
in mdx dystrophic muscle undergoing necrosis (Marotta et al., 2009). These two 
studies suggest a potential role for Adamts5 mediated ECM remodelling in muscle 
development, regeneration and disease, however little else is known about Adamts5 
in skeletal muscle. 
The C2C12 cell line was used to investigate the expression and function of Adamts5 
in myoblast fusion and myogenic differentiation in an in vitro model. Expression of 
Adamts5 and versican were found to be increased during C2C12 myogenic 
differentiation. Immunostaining for versikine, the G1-DPEAAE versican fragment 
formed by ADAMTS proteolysis, demonstrated its localisation between C2C12 cells 
aligned to fuse into myotubes. Silencing of Adamts5 using siRNA resulted in decreased 
myoblast fusion, while addition of ADAMTS5 after its silencing, restored myoblast 
fusion towards control levels. Using a particle exclusion assay, it was also shown that 
Adamts5 silencing resulted in an accumulation of ECM surrounding C2C12 cells. We 
therefore propose that myoblast fusion was decreased with Adamts5 silencing due to 
the accumulation of ECM inhibiting the cell-cell contact necessary for myoblast 
fusion. 
Primary cultures isolated from skeletal muscle of Adamts5-/- and C57Bl/6 mice were 
used to further investigate the expression and function of Adamts5 in myogenic 
differentiation. Adamts5 was not expressed by desmin+ primary myoblasts but was 
instead expressed by TCF4+ MCT fibroblasts. Fusion of primary myoblasts was not 
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affected by Adamts5 deletion, consistent with the lack of Adamts5 expression by 
primary myoblasts. The effect of Adamts5 deletion on MCT fibroblast proliferation 
was also investigated but there was no change in proliferation compared to MCT 
fibroblasts isolated from C57Bl/6 wild-type controls. 
The expression of Adamts5 and its known skeletal muscle substrates was also 
investigated in the mdx mouse model of Duchenne muscular dystrophy. Adamts5 
expression was decreased in the mdx mouse, compared to C57Bl/10 wild-type control, 
at two and three weeks, correlating with the acute onset of myofibre necrosis at those 
ages. At other ages, there was no difference in Adamts5 expression in the mdx mouse 
when compared to age-matched C57Bl/10 wild-type controls. Adamts5 expression 
appeared to be localised to multiple cell types in dystrophic muscle using LacZ 
reporter activity in mdx:Adamts5-/- mice. This observation however, needs to be 
confirmed by double immunostaining using an antibody for -galactosidase (an 
alternative approach used to detect LacZ reporter activity) together with antibodies 
for cell-specific markers such as TCF4 for MCT fibroblasts. Immunolocalisation of 
versikine demonstrated its expression in areas that would potentially co-localise with 
Adamts5, particularly the putative expression by endothelial and interstitial cells. 
Again, in order to confirm this observation, double immunostaining for versikine and 
-galactosidase would be required to test this. 
Adamts5 expression and function in muscle regeneration was investigated using the 
notexin in vivo model of muscle regeneration. Adamts5 also appeared to be expressed 
by multiple cell types in regenerating muscle, however this was not confirmed by 
double immunostaining. Expression of biglycan progressively increased over time in 




The effect of Adamts5 deletion on muscle regeneration was also investigated. There 
was no difference in F4/80+ cells three days after notexin-induced muscle regeneration 
and also no difference in the expression of Emr1 (F4/80 transcript) or interleukin-10, 
which is known to regulate macrophage polarisation towards the M2 phenotype 
(Deng et al., 2012). Furthermore, there was no difference in regenerative myogenesis 
with Adamts5 deletion. The size of newly regenerating neomyofibres was unchanged, 
as was the expression of Myh3 and Myogenin. Myofibre size 14 days after notexin-
induced muscle regeneration was also not changed suggesting that Adamts5 deletion 
does not affect muscle regeneration in this model. 
Although the current study showed that Adamts5 deletion did not affect notexin-
induced muscle regeneration, it is likely that perturbed ECM remodelling by 
ADAMTS proteoglycanases may impact on muscle regeneration and DMD pathology. 
Given that Adamts5 deletion did not affect muscle regeneration using the notexin 
model, it may be that other related ADAMTS proteoglycanases compensated for the 
loss of Adamts5 in the Adamts5-/- mice. To test this, future work could induce muscle 
regeneration with notexin using combinatorial Adamts deficient mice to determine 
whether multiple ADAMTS proteoglycanases may cooperate in muscle regeneration 
such as has been demonstrated in regression of interdigital webs during embryonic 
limb development (McCulloch et al., 2009b) and formation of the palate (Enomoto et 
al., 2010). 
An alternative approach, focussed on ADAMTS proteolysis of versican, could be to 
generate a tamoxifen-inducible versican knockin mouse with a mutation which 
renders versican resistant to processing by ADAMTS proteoglycanases. Using the 
notexin model of muscle regeneration in such a mouse model would allow the effect 
of ADAMTS proteolysis of versican to be investigated. This approach would be 
advantageous since it would allow the investigation to be focussed on the proteolysis 
of the substrate irrespective of the protease targeting it. A similar approach has been 
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used to generate an aggrecan knockin mouse which was used in arthritis studies (Little 
et al., 2007). 
A recent study has identified ADAMTS5 as a therapy-responsive serum biomarker 
(Coenen-Stass et al., 2015). The study found that ADAMTS5 was increased in serum 
of mdx mice compared to C57Bl/10 wild type controls. They also restored dystrophin 
levels in mdx mice with exon skipping and showed that serum ADAMTS5 levels 
decreased towards wild type levels, showing that ADAMTS5 may be potentially used 
as a clinical biomarker. Furthermore, ADAMTS5 was measured in patient serum 
which showed increased levels in DMD patient serum compared to control (Coenen-
Stass et al., 2015). Whether Adamts5 may play a role in muscular dystrophy is yet to 
be seen and further investigations using the mdx:Adamts5-/- mouse are required, and 
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